CA2240845C - New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds - Google Patents

New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds Download PDF

Info

Publication number
CA2240845C
CA2240845C CA002240845A CA2240845A CA2240845C CA 2240845 C CA2240845 C CA 2240845C CA 002240845 A CA002240845 A CA 002240845A CA 2240845 A CA2240845 A CA 2240845A CA 2240845 C CA2240845 C CA 2240845C
Authority
CA
Canada
Prior art keywords
phenyl
alkyl
substituted
compound
bicycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002240845A
Other languages
French (fr)
Other versions
CA2240845A1 (en
Inventor
Elmar Bosies
Angelika Esswein
Frank Grams
Hans-Willi Krell
Ernesto Menta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19548624A external-priority patent/DE19548624A1/en
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of CA2240845A1 publication Critical patent/CA2240845A1/en
Application granted granted Critical
Publication of CA2240845C publication Critical patent/CA2240845C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of formula (I) in which X, Y and Z are independently of one another oxygen, sulphur or NH; R1 represents a group W-V: W is a valence dash or a straight-chained or branched C1-C8 alkyl or a C2-C8 alkenyl group which is optionally once or several times substituted, V is an optionally substituted monocycle or bicycle which can contain one or several heteroatoms, or W-V is a C1-C20 alkyl group which can be interrupted by heteroatoms, one or several carbon atoms are optionally substituted; R2 and R3 represent hydrogen or one of the two represents lower alkyl or lower aryl; R4 and R5 denote independently of each other for A-D, wherein A represents a dash alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxy-carbonyl, alkylaminothiocarbonyl, aminothio-carbonyl which is optionally once or several times substituted; D represents a hydrogen, monocycle or bicycle, the monocycle or bicycle is optionally once or several times interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted, or R4 and R5 together with the adjacent N atom form a ring; pharmacologically acceptable salts and prodrugs thereof and optically active forms, processes for their production and pharmaceutical agents which contain these compounds having a matrix metalloprotease-inhibitory action.

Description

W O 97/23465 PCTlEP96/05766 New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds In normal tissue there is an equilibrium between synthesis and degradation.
Extracellular matrix is degraded by proteases which belong to at least three groups of matrix metalloproteases. These are the collagenases, gelatinases and stromelysins.
Normally there are specific inhibitors for these catabolic enzymes such as oc2 macroglobulines and MMP (= tissue inhibitor of metalloproteases (MMP}) so that an excessive degradation of extracellular matrix does not occur. A related group of proteases is the adamalysins. A
prominent member of the adamalysins is TACE (TNF-oc-converting enzyme}.
At least 11 different and yet highly homologous MMP species have been characterized, including the interstitial fibroblast collagenase (MMP-I, HFC), the neutrophil coIlagenase (MMP-8, HNC), two gelatinases, stromelysins (such as HSL-I ) and HPUMP (for a recent review, see Birkedal-Hansen, H., Moore, W.G.L, Bodden, M.K., Windsor, L.J., Birkedal-Hansen; B., DeCarIo, A., Engler, 3.A., Critical Rev.
Oral Biol.Med. (I993) 4, I97-250. These proteinases share a number of structural and functional features but differ somewhat in their substrate specificity. Only HNC and HFC
are capable of cleaving type 1, II and III native triple-helical collagens at a single bond with the production of fragments 3/4 and I/4 of the native chain length. This lowers the collagen melting point and makes them accessible to further attack by other matrix degrading enzymes.
However, the uncontrolled excessive degradation of this matrix is a characteristic of many pathological states such as e.g. in the clinical picture of rheumatoid arthritis, 3 0 osteoarthritis, multiple sclerosis, in the formation of tumour metastases, corneal ulceration, inflamative diseases and invasion and in diseases of the bone and teeth.
It can be assumed that the pathogenesis of these clinical pictures can be favourably influenced by the administration of matrix metailoprotease inhibitors. A
number of compounds in the meantime are known in the literature (see e.g. the review article of Nigel RA Beeley et al. Curr. Opin. they. Patents 4 (I), 7 (1994)) or are described in the patent literature, these mainly being peptides with a hydroxamic acid residue.
a thiol or phosphine group as a zinc binding group (see e.g. WO-A-9209563 by Glycomed, EP-A-497 192 by Hoffmann-LaRoche, WO-A-9005719 by British Biotechnology, EP-A-489 577 by Celltech, EP-A-320 I 18 by Beecham, US-A-459 5700 by Searle among others).
Some of these compounds have a high activity as inhibitors of matrix metalloproteases but only have a very low oral availability.
It has now been found that the claimed new barbituric acid derivatives are very efficacious as matrix metalIo-protease inhibitors and have a good oral availability.
The present invention therefore concerns substances of the general formula I
R~

Y Z
~~N N~~
(I) X
in which X, Y and Z are independently of one another oxygen, sulphur or NH, Rl represents a group W-V
W is a valence dash or a straight-chained or branched C1-C8 alkyl or a CZ-C8 alkenyl group which is optionally once or several times substituted, V is an optionally substituted monocycle or bicycle which can contain one or several heteroatoms, or W-V is a Cl-C20 akyl group which can be interrupted by heteroatoms, one or several carbon atoms are optionally substituted, ' 3 0 RZ and R3 represent hydrogen or one of the two represents lower alkyl or lower acyl WO 97/23465 PC'I7EP96/45766 R4 and RS denote independently of each other for A-D wherein A represents a dash~alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxy-carbonyl, alkylaminothiocarbonyl, aminothio-carbonyl which is optionally once or several times substituted, D represents a hydrogen, mono or bicycle, the monocycle or bicycle is optionally once or several times interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted, or R4 and R5 together with the nitrogen atom to which they are bound represent a ring which optionally can be interrupted by a further N atom, said ring can be condensed to a monocycle or bicycle; said ring can optionally be substituted once or several times independently by the residues hydroxy, alkoxy, amino, alkylamino, dialkylamino, nitril or by E-G wherein E represents a dash alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxy-carbonyl, alkylaminothiocarbonyl, aminothiocarbonyl which is optionally substituted; G
represents a hydrogen, mono or bicycle, the monocycle or bicycle is optionally once or several times 2 0 interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted, pharmacologically acceptable salts or prodrugs thereof as well as the use of these compounds to produce pharmaceutical agents.
The monocycie listed in the case of RI, R4 and R~ is understood as saturated or unsaturated ring systems with 3 - 8, preferably 5 - 7 carbon atoms which can optionally be interrupted one or several times by heteroatoms such as nitrogen, oxygen or sulphur 3 0 in particular a cyclopentyl, cyclohexyl, cycloheptyl, morpholinyl, thiamorpholinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furyl, thiophenyl, imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl or 1,2,4-triazoiyl residue. Lower alkyl, alkoxy and halogen come above ail into consideration as substituents.
The bicycle listed under R1, R4 and R5, is understood to be a condensed bicycle or a bicycle of the type monocycle,-L-monocycle2, wherein L denotes a valence dash alkyl group, CZ-C4 an alkenyl group, an oxygen or -C(O)-group.
The bicycle is preferably a residue such as a naphthyl, tetrahydronaphthyl, dekalinyl, quinolinyl, isoquinolinyl, tetrahydroquino-linyl, tetrahydroisoquinolinyl, indolyl, bettzimidazolyl, indazolyl, oxindolyl, benzofuranyl, benzothiophenyl, benzthiazolyI, benzoxazolyl, purinyl, biphenyl or (4-phenoxy)phenyl residue and in particular a naphthyl, biphenyl, quinoiinyi, isoquinolinyt, tetrahydroquinolinyl, indolyl or benzimidazolyl residue.
The residues listed under R1, R4 and RS can optionally be substituted once or several times by halogen, hydroxy, thin, alkyl, hydroxyalkyi, alkoxy, alkylthio, alkylsulfinyl, alkyl-sulfonyl, amino, alkylamino, dialkylamino, nitro, carboxyl, carboxamido, alkoxy-carbonyl, amino or aminocarbonyl optionally substituted once or twice by lower alkyl, nitrite, oxo, thiocarboxamido, alkoyxythiocarbonyl, alkmercaptocarbonyl, phosphono, alkylphosphono, dialkylphosphono, alkylsulfonylamido, arylamino, aryl, hetaryl, aryloxy, arylthio, arylsulftnyl, arylsulfonyl or acyl.
2 0 In this case the halogen, hydroxy, oxo, thio, alkoxy, alkylthio, amino, aminocarbonyl, carboxyl and acyl groups are preferred.
Lower alkyl denotes C,-C~-Alkyl, preferred methyl, ethyl, propyl, isopropyl or tert.-butyl.
Lower acyl in the residues R2 and R3 above all denotes for -C{O)-C,-C6-alkyl or -C(O)H, preferred for an acetyl group.
The alkyl residues in R,, R4 and RS can optionally be interrupted once or several time by 3 0 heteroatoms {O, S, NH).
Alkyl in the residues R4 and RS denotes as such or in combination with alkoxy, alkylthio, aryIsulfonyl, alkylsulfonyl, alkylaminocarbonyl, arylaminocarbonyl, alkylamino, alkoxycarbonyl, aryloxycarbonyl, alkylaminothiocarbonyl, arylaminothiocarbonyl a straight-chained, branched, saturated or unsaturated residue with 1 - 11, preferably 1 - 8 carbon atoms such as e.g. a methyl, ethyl, propyl, pentyl, octyl, allyl, propargyl, 2,4-pentadienyl, isopropyl, sec. butyl, 3-methylbutyl, 2-hydroxyhexyl and in particular a methyl, propyl, isopropyl, pentyl, octyl, allyl, 3-methyibutyl, 2-hydroxyhexyl and propargyl residue.
Aryl, also in combination with aryloxy, arylthio, arylsulfonyl, arylaminocarbonyl, aryloxycarbonyl, arylaminothiocarbonyl is understood as a phenyl or naphthyl residue which can optionally be substituted in particular by halogen, lower alkyl or alkoxy.
The C 1-C2p alkyl group listed for RI is a straight-chained or branched saturated residue such as e.g. a methyl, ethyl, propyl, butyl, pentyl, octyl, decyl, undecyl, isobutyl, 3-methylbutyl or 7-methyloctyl group. Hydroxy and amino residues come above all into consideration as substituents. The alkyl chains can be interrupted once or several times by oxygen, nitrogen or sulphur. The preferred heteroatom interruption is oxygen (ether linkage) or -C(O)NH- (amid linkage). The most preferred heteroatom interrupted residues are -(CHZCH20}n-(CHZ)mH and n= 2 or 3 and m = I or 2.
W of R, is preferrabiy a methyl, ethyl, butyl or hexyi residue; V is in particular a phenyl, Pyridyf, imidazolyl residue which can optionally be substituted above all by lower alkyl, hydroxy, alkoxyamid, sulfonamide or halogen. The most preferred Rl residues are C6-C I2-A,lkyi residue or a -(CHZ)» C6H4-(CHz)mH residue, wherein m and n are equal or 2 0 less than 8, the (CHz)-group is optionally interrupted by oxygen, sulfur, or NH and one or two carbons of the phenyl ring are substituted for N-heteroatoms. The aikyI, aryl, hetaryl groups are optionally substituted by small polar substituents.
The most preferred R, residues are n-Octyl, n-Decyl, Biphenyl or octyl or decyl type residues showing two or three oxygen heteroatoms like 2-(2-(2-methoxyethoxy)-ethoxy}ethyl, 2-(2-ethoxyethoxy)ethyl or biphenyl-type residues showing one or two nitrogen heteroatoms. The bridging monocycle is optionally ortho substituted and the terminal monocycle of the biphenyl or biphenyl type residue is optionally ortho or para substituted by a small, polar substituent like NH2, -N02, -S02NHa, SOaCH3, Acetyl, 3 0 Hydroxy, Methoxy, Ethoxy or Nitril-group. The para substitution of the terminal monocycle is more preferred.
Halogen is understood as chlorine, bromine, iodine and preferably chlorine.
3 5 The hetaryl residues listed for Rq. and RS denote preferred for a pyridine, pyrazine, piperazine, imidazole, thiazoie, thiophene or indole ring preferably a pyridine, imidazole and thiophene ring.

-b-The acyi residue listed for the residues R4 and RS is a residue with 1 - 10, preferably 6 -8 carbon atoms such as e.g. a hexanoyl or octanoyl residue. The alkyl group can be interrupted once or several times by heteroatoms or heteroatom groups like S, O, NH, SO,, amido or carbonyl. These residues can be substituted by amino groups, alkyl groups, aryl groups, arylalkyl groups, alkylamino groups, dialkyIamino groups, alkoxy groups and aromatic compounds. These are then amino acid residues preferably a phenylalanine and tryptophan residue in this case.
If R4 and RS form a ring together with the nitrogen atom to which they are bound, these are 5 - 7-membered rings preferably a six-membered ring. The piperidine, piperazine, tetrahydroquinoiine and tetrahydroiso-quinoline, bicyclo(9.4.0)pentadecyl and 1,2,3,4-tetrahydrobenzo(g)isoquinoline rings are preferred.
If compounds of the general formula I contain one or several asymmetric carbon atoms, the optically active compounds of the general formula I are also a subject matter of the present invention.
Independently of each other the preferred meaning for X, Y, Z is oxygen, for Rz and R3 it is hydrogen. A more preferred combination is X, Y and Z equal each oxygen and R2 is 2 0 identical to R3 and both mean hydrogen.
It is also preferred that R., and RS do not both represent hydrogen.
The term "several" means in connection with heteroatoms in monocycles or bicycles preferred one, two or three more preferred one or two, the most preferred heteroatom is nitrogen.
The term "several" means in connection with substituents or substitution preferred one to five, more preferred one, two or three most preferred one or two.
The term "heteroatom" in connection with alkyl or acyl groups means preferred oxygen 3 0 or NH, more preferred oxygen.
Substitutions of monocycles or bicycles in R~, R4 and RS are halogen, nitro, hydroxy, alkoxy, amino, alkylamino, dialkylamino, halogenmethyi, dihalogenmethyl, trihalogenmethyl, phosphono, aikylphosphono, dialkylphosphono, S02NH2, S02NH(alkyl), SOZN(alkyi)z, SOZ(alkyl), acetyl, formyl, nitril, COOH, COOalkyl, -OC(O)alkyl, -NHC(O)Oalkyl, OC(O)O-aryl, -NHC(S)NH2, -NHC{S)NHaIkyl, -NHC(O)-aryl.

The preferred ring structure formed together with the nitrogen, Rø and R5, is piperazin or piperidin, both of which are substituted preferrably at the 4-position. In the case of piperidin the 4 position is optionally substituted by a second substitute hydroxy, amino, alkylamino, alkyiamino, dialkylamino or aIkoxy. The 4 position of piperidin may also form a double bond with the substituent of the 4 position.
Preferred substitution of the 4 position of piperidin or piperazin are 6-membered aromatic monocycles which are more preferred substituted in para position by small polar substitutions as hydroxy, lower alkoxy, amino, lower alkylamino, lower dialkylamino, nitro, nitrilo, SOaNH2, SOzNH lower alkyl, SOz lower alkyl. The membered aromatic monocycle is preferrably bound to the 4 position via a valence bond or a lower aikyI spacer.
In the case that R4 is hydrogen a lower alkyl a lower alkylaryl, then RS is preferred a acyl derivate preferrably substituted with a monocyle or lower alkylaryl; or a -CHRso-CHRsI-NRsz-Rs3 wherein Rso and Rs 1 denote independently of each other for hydrogen, lower alkyl a lower alkoxy. Rs2 denotes for hydrogen or lower alkyl, Rs3 denotes a 6-membered aromatic monocycle which is optionally once or several times substituted and bound to the nitogen preferrably via a valence bond or a lower alkyl spacer.
The most preferred combination of meanings in general formula I are X equals Y equals Z equals oxygen and R2 equals Rz equals hydrogen and Rl equals n-Octyl, n-Decyl, Biphenyl or octyl or decyl type residues showing two or 2 5 three oxygen heteroatoms like 2-(2-(2-methoxyethoxy)-ethoxy)ethyl, 2-(2-ethoxyethoxy)ethyl or biphenyl-type residues showing one or two nitrogen heteroatoms;
wherein the bridging monocycIe is optionally ortho substituted and the terminal monocycle of the biphenyl or biphenyl type residue is optionally ortho or preferred para substituted by a small, polar substituent like NHZ, -N02, -SOZNH2, SOzCH3, Acetyl, 3 0 Hydroxy, Methoxy, Ethoxy or Nitril-group and R4 and Rs form together with the nitrogen to which they are bound a piperazin or piperidin both of which are substituted in the 4 position with a phenyl, pyridyl or pyrazidyl ring which is preferred para substituted by a small polar substituent; in the case of piperidin the 4 position may be additionally sustituted by hydroxy, lower alkoxy, nitril 3 5 or amin which may be mono- or disubstituted by lower alkyl.

_g_ Compounds of the general formula I can be synthesized by well-known processes preferably in that a) compounds of the general formula II
' Y Z
~~N~N~~
{II) X
in which X, Y, Z, R 1, R2 and R3 have the above-mentioned meanings and T
represents a leaving group such as Hal or OS02Rb,Hai denoting chlorine, bromine or iodine and R6 denoting an aryl or a methyl residue, are reacted with a compound of the general formula III
~ R4 HN
Rs (III) in which R4 and RS have the meanings stated above and optionally converted into pharmacologically acceptable salts or b) compounds of the general formula IV

Ri N-Rs Y Z
OR.~ OR., {IV) in which RI, R4 and RS have the above-mentioned meanings, Y and Z
independently of one another represent oxygen, sulphur or a NH group and R~ = methyl, ethyl or phenyl, 2 5 is reacted with a compound of the general formula V

- X (V) ~ in which R2, R3 and X have the above-mentioned meanings and optionally convened into pharmacologically acceptable salts or n the case that R4 and/or RS represent an acyl, alkylsulfonyl, arylsulfonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminothiocarbonyl or arylaminothiocarbonyl residue c) a compound of the general formula VI
Rt ~a Y Z
~~N~N~~
(VI) X

in which X, Y, Z, R1, R2 and R3 have the above-mentioned meanings, is reacted with a compound of the general formula VII or VIII
Rg D Hal (VII) RSN-- CwA (VIII) in which Rg represents an optionally substituted alkyl or aryl residue, D =
C{O), O-C{O), S02 or a valency dash. Hal = chlorine, bromine or iodine and A represents oxygen or sulphur 2 5 and optionally converted into pharmacologically acceptable salts.
Compounds of the general formula II are known in the literature. Thus for example 2,4,6-pyrimidine triones brominated in the 5-position can be synthesized by reacting the appropriate bromomalonic acid dialkyl esters with urea (e.g. Acta Chim. Acad.
Sci.
3 0 Hung. 107 (~), 13 9 ( I 98 I )). The corresponding brominated or chlorinated compounds of the general formula II can be obtained by reacting 2,4,6-pyrimidine-triones substituted by _ 10_ R1 in the 5-position with bromine (analogous to J. pr. Chemie 136, 329 (1933) or J.
Chem. Soc. 1931, 1870) or sulfuryl chloride (J. Chem. Soc. 1938. 1622). In the same manner one can synthesize the 2-imino-4,6-pyrimidine-diones of the general formula II
correspondingly halogenated in the 5-position analogously to Collect. Czech.
Comm. 48 ( 1 ), 299 ( I933). The reaction of 2-this-4,6-pyrimidine-diones substituted by RI in the 5-position with bromine in glacial acetic acid (analogously to Am. Chem. J. 34, 186} leads to the compounds of the general formula II correspondingly brominated in the 5-position.
1 o Amines of the general formula III are commercially available or are usually known in the literature.
Compounds of the general formula IV are reacted according to known methods with ureas (see for example J. Med. Chem. 10, 1078 (1967} or Helvetica Chim. Acta 34. 459 ( 1959) or Pharmacie 3 8 ( I ), 65 ( 1983 )), thioureas (see for example Indian J. Chem. 24 (10), 1094 (1985} or 3. Het. Chem. 18 (3), 635 (1981)) or guanidines (see for example Collect. Czech. Chem. Comm. 45 (12), 3583 {1980)) ofthe general formula V.
The reactions are usually carried out in an alcohol such as methanol, ethanol or butanol 2 0 in the presence of an appropriate sodium alcoholate at temperatures between 40°C and 100°C and in the case of the guanidines also at temperatures of up to 200°C (under pressure). In the case of the thioureas the process is frequently earned out in the presence of acetyl chloride (also as a solvent}.
Compounds ofthe general formula IV are known from the literature or can be produced according to processes known from the literature. They can be synthesized for example by weak acidic hydrolysis of the corresponding bislactim ethers (see J. Chem.
Soc.
Chem. Comm. 5, 400 (1990)). Other methods of synthesis are for example described in Farmaco Ed. Sci. 31 (7), 478 ( 1976) or Aust. J. Chem., 23 (6), 1229 (1970).
Ureas, thioureas and guanidines of the general formula V are commercially available.
Compounds of the general formula VI can easily be synthesized by reacting an appropriate substituted acetamidomalonic ester according to process b) and subsequent hydrolytic cleavage of the acetyl group {see Can. J. Chem. 42 {3), 605 (1964)).

Carboxylic acid chlorides of the general formula VII are known or can be synthesized by generally known methods from the corresponding carboxylic acids. The reaction is usually carried out with thionyl chloride or phosphorus tribromide or phosphorus pentabromide or pentachloride in inert solvents such as dichloromethane, diethyl ether, dioxane or tetrahydrofuran at temperatures of 0°C to 50°C, preferably between 20°C and 40°C.
Chloroformic acid esters of the general formula VII are known in the literature or can be obtained by generally known methods from the corresponding alcohols by reaction with phosgene or diphosgene. The reaction proceeds in inert solvents such as e.g.
diethyl ether, dichloromethane, dioxane, tetrahydrofuran or toluene at temperatures between -20°C and 20°C. In the case of phosgene the reaction is carried out in the presence of bases, usually tertiary amines such as e.g. triethylamine or pyridine.
Suifonic acid chlorides of the general formula VII are known or can be synthesized analogously to described methods from the corresponding sulfonic acids by reaction with phosphorus pentachloride or thionyl chloride. The reaction is usually carned out in an inert solvent such as e.g. dimethylformamide or also without a solvent at temperatures of 20°C to 180°C, preferably at 50°C to 100°C.
Isocyanates of the general formula VIII are known or can be synthesized by methods known in the literature. Thus for example appropriate alkyl halogenides of the general formula Rg-Hal can be reacted with potassium cyanate analogously to Synthesis 1978, 760. Further methods are to react an acid amide of the general formula Rg-CONH2 with 2 5 oxalyl chloride, to thermally decompose an acid azide of the general formula Rg-CON3 or to react an amine of the general formula Rg-NH2 with phosgene (analogously to Ann.
Chem. 562, 110).
Isothiocyanates of the general formula VIII are known in the literature or can be 3 0 synthesized analogously to known processes. An amine of the general formula Rg-NH2 is preferably allowed to react with carbon disulphide under alkaline conditions analogously to Chem. Ber. 74 1375.
The reaction of carboxylic acid halogenides, sulfonic acid halogenides or chloroformic 3 5 acid esters of the general formula VII with amines of the general formula VI is usually carried out in a solvent such as dichloromethane, dimethylformamide or pyridine with addition of an auxiliary base such as triethylamine or 4-dimethylaminopyridine at a temperature between -10°C and 50°C, preferably at room temperature.
Compounds of the general formula I can contain one or several chiral centres and can then be present in a racemic or in an optically active form. The racemates can be separated according to known methods into the enantiomers. Preferably diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid.
malic acid, lactic acid or camphorsulfonic acid or with an optically active amine such as e.g. D- or L-oc-phenyl-ethylamine, ephedrine, quinidine or cinchonidine.
Alkaline salts, earth alkaline salts like Ca or Mg salts, ammonium salts, acetates or hydrochlorides are mainly used as pharmacologically acceptable salts which are produced in the usual manner e.g. by tritrating the compounds with inorganic or organic bases or inorganic acids such as e.g. sodium hydroxide, potassium hydroxide, aqueous ammonia, C 1-C4-alkyl-amines such as e.g. triethylamine or hydrochloric acid. The salts are usually purified by reprecipitation from water/acetone.
The new substances of formula 1 and salts thereof according to the invention can be 2 0 administered enterally or parenterally in a liquid or solid form. In this connection all the usual forms of administration come into consideration such as for example tablets, capsules, coated tablets, syrups, solutions, suspension etc. Water which contains additives such as stabilizers, solubilizers and buffers that are usual in injection solutions is preferably used as the injection medium.
Such additives are e.g. tartrate and citrate buffer, ethanol, complexing agents (such a ethylenediaminetetra-acetic acid and non-toxic salts thereof), high-molecular polymers (such as liquid polyethylene oxide) to regulate viscosity. Liquid earner substances for injection solutions have to be sterile and are preferably dispensed into ampoules. Solid 3 0 carrier substances are e.g. starch, lactose, mannitol, methylcellulose, talcum, highly dispersed silicic acids, higher molecular fatty acids (such as stearic acid), gelatins, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high-molecular polymers (such as polyethylene glycols); suitable preparations for oral application can optionally also contain flavourings and sweeteners.
The dosage can depend on various factors such as manner of administration, species, age and/or individual state of health. The doses to be administered daily are about 10-1000 mg/human, preferably 100-500 mg/human and can be taken singly or distributed over several administrations.
Prodrugs of the compounds of the invention are such which are converted in vivo to the pharmacological active compound. The most common prodrugs are carboxylic acid esters.
Within the sense of the present invention the following barbituric acid derivatives are preferred in addition to the compounds mentioned in the examples and compounds that can be derived by combining all meanings of substituents mentioned in the claims:
1. 5-(N-benzyl-N-octyl}-5-phenyl-barbituric acid 2. 5-(N-benzyl-N-phenethyl)-5-phenyl-barbituric acid 3. 5-(N-benzyl-N-[2-(4-pyridyl)ethyl)]-5-phenyl-barbituric acid 4. 5-(N-benzyl-N-[2-(3-pyridyl)ethyl]-5-phenyl-barbituric acid 5. 5-(N-benzyI-N-[2-(2-pyridyl)ethyl]-5-phenyl-barbituric acid 6. S-(N-benzyl-N-[2-(2-thiophenyl)ethyl]-5-phenyl-barbituric acid 7. 5-[N-(3-methylbutyl)-N-(3-phenylpropyl)]-5-phenyl-barbituric acid 8. 5-(N-benzyl-N-[3-(4-pyridyl)propyl])-5-phenyl-barbituric acid 2 0 9. 5-(N-benzyl-N-[2-(2-imidazolyi)ethyl])-5-phenyl-barbituric acid 10. 5-(N-benzyl-N-[2-{ I -imidazolyl)ethyl])-5-phenyl-barbituric acid 11. 5-{N-butyl-N-phenylalaninyl)-5-phenyl-barbituric acid 12. 5-(N-butyl-N-tryptophanyl)-5-phenyl-barbituric acid 13. 5-(N-benzyi-N-cyclohexyl)-5-phenyl-barbituric acid 14. 5-[N-benzyl-N-(2-pyridyl)]-5-phenyl-barbituric acid 15. 5-[N-butyl-N-(4-piperidinyl)]-5-phenyl-barbituric acid 16. 5-[N-benzyl-N-(2-imidazolyl)]-5-phenyl-barbituric acid 17. 5-(N-octyl-N-phenyl)-5-phenyl-barbituric acid 18. 5-[N-(2-naphthyl)-N-propyl]-5-phenyl-barbituric acid 3 0 19. 5-[N-(4-tetrahydroquinolinyl)-N-propyl]-5-phenyl-barbituric acid 20. 5-[N-benzyl-N-(2-thiophenyl)]-5-phenyl-barbituric acid 21. 5-[N-(3-methylbutyl)-N-[3-(4-pyridyl)propyl)]-5-phenyl-barbituric acid 22. 5-[N-(7-methyloctyl)-N-[3-(2-pyridyl)propyl)]-5-phenyl-barbituric acid 23. 5-{N-(2-hydroxyhexyl)-N-[3-(3-pyridyl)propyl])-5-phenyl-barbituric acid 3 5 24. 5-(N-benzyl-N-hexanoyl)-5-phenyl-barbituric acid 25. 5-(N-benzyl-N-octanoyl)-5-phenyl-barbituric acid 26. 5-(N-benzyl-N-octanesulfonyl)-5-phenyl-barbituric acid 27. 5-[N-butyl-N-(2-naphthylsulfonyl)]-5-phenyl-barbituric acid 28. 5-(N-hexyloxycarbonyl-N-propyl)-5-phenyl-barbituric acid 29. 5-(N-(4-methoxy-phenylsulfonyl)-N-hexyl]-5-phenyl-barbituric acid 30. ~-[N-(4-butoxy-phenylsulfonyl)]-N-hexyI]-5-phenyl-barbituric acid 31. 5-[N-benzyl-N-(2-phenethyl)]-5-(4-pyridyl) barbituric acid 32. 5-[N-benzyl-N-(2-phenethyl)]-5-(2-pyridyl) barbituric acid 33. 5-(N,N-dipentyl)-5-(4-piperidinyl)barbituric acid 34. 5-(N,N-dioctyl)-5-(2-thiophenyl)barbituric acid 35. 5-{N-benzyl-N-[2-(2-pyridyl)ethyl]-5-{3-imidazolyl) barbituric acid 36. 5-[1-(4-hydroxy)piperidinyl]-5-(4-pyridyl) barbituric acid 37. 5-[ I -{4-hydroxy)piperidinyl]-5-(3-pyridyl) barbituric acid 38. 5-[I-(4-hydroxy)piperidinyl]-5-(2-pyridyl) barbituric acid 39. 5-[1-(4-hydroxy)piperidinyl]-5-(4-piperidinyl} barbituric acid 40. 5-[ 1-(4-hydroxy)piperidinyl]-5-{2-thiophenyl) barbituric acid 41. 5-[1-(4-hydroxy)piperidinyl]-5-(4-imidazolyl) barbituric acid 42. 5-benzyl-5-[ I -{4-hydroxy)piperidinyl]barbituric acid 43. 5-[1-(4-hydroxy)piperidinyl]-5-(2-phenethyl) barbituric acid 44. 5-[I-{4-hydroxy)piperidinyl]-5-(I-naphthyl) barbituric acid 45. 5-[ 1-(4-hydroxy)piperidinyl]-5-(2-naphthyl) barbituric acid 2 0 46. 5-(2-quinolinyl)-5-[ 1-(4-hydroxy)piperidinyl] barbituric acid 47. 5-[i-(4-hydroxy)piperidinyl]-5-(1-isoquinolinyl) barbituric acid 48. 5-[I-(4-hydroxy)piperidinyl]-5-(2-tetrahydro-quinolinyl)barbituric acid 49. 5-(2-indolyl)-5-[ 1-(4-hydroxy)piperidinyl] barbituric acid 50. 5-(2-benzimidazoiyl)-5-[i-(4-hydroxy)piperidinyI] barbituric acid 2 5 51. 5-( 1-[4-(2-hydroxyethyl)piperazinyl])-5-octyl-barbituric acid 52. 5-decyl-5-(1-[4-(2-hydroxyethyl)piperazinyl]) barbituric acid 53. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-undecyl-barbituric acid 54. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(7-methyl-octyl)barbituric acid 55. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(8-hydroxy-octyl)barbituric acid 3 0 56. 5-(8-aminooctyl)-5-( I-[4-(2-hydroxyethyl) piperazinyl])barbituric acid 57. 5-(1-[4-(2-hydroxyethyl}piperazinyl])-5-(2-phen-ethyl)barbituric acid 58. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-{4-phenyl-butyl)barbituric acid 59. 5-{1-[4-(2-hydroxyethyl)piperazinyl])-5-{6-phenyl-hexyl}barbituric acid 60. 5-( I -[4-(2-hydroxyethyl)piperazinyl])-5-[6-(4-methylphenyl)hexyl]barbituric 3 5 acid 61. 5-{I-[4-(2-hydroxyethyl)piperazinyl])-5-(2-pyridylmethyl)barbituric acid 62. 5-{1-[4-(2-hydroxyethyl)piperazinyl])-S-(4-imidazolylmethyl}barbituric acid WO 97/23465 PCT/EP96/05~66 63. 5-(I-[4-(2-hydroxyethyl)piperazinyl])-S-(I-imidazolylmethyl)barbituric acid 64. 5-phenyl-5-( 1-(4-propyl)piperazinyl]barbituric acid 6S. S-phenyl-S-( 1-tetrahydroquinoiinyl)barbituric acid 66. S-phenyl-5-(1-tetrahydroisoquinolinyl)barbituric acid 67. S-phenyl-5-[2-(1,2,3,4-tetrahydrobenzo(g)iso-quinolinyl]barbituric acid 68. S-[2-(Z-aza-bicyclo[9.4.0]pentadecyl)]-S-phenyl-barbituric acid 69. S-[2-(2,11-diaza-12-oxo-bicyclo[9.4.0]pentadecyl)]-5-phenyl-barbituric acid 70. 5-{1-[4-(I-oxo-propyl)]piperidinyl)-5-phenyl-barbituric acid 71. S-[I-(3-oxo-4-propyl)]piperidinyl]-5-phenyl-barbituric acid 72. 5-phenyl-5-[1-(4-propyl)piperazinyl]barbituric acid 73. S-[I-(3,S-dihydroxy-4-propyl)piperidinyl]-S-phenyl-barbituric acid 74. 5-(4-chlorophenyl}-5-[I-(4-hydroxy)piperidinyl] barbituric acid 75. 5-{4-chlorobenzyl)-5-[1-(4-hydroxy)piperidinyl] barbituric acid 76. S-[1-(4-hydroxy)piperidinyl]-5-(4-methoxybenzyl) barbituric acid 77. 3-methyl-5-[ 1-(4-hydroxy}piperidinyl]-S-phenyl-barbituric acid 78. 1-isopropyl-5-[ I-{4-hydroxy)piperidinyl]-5-phenyl-barbituric acid 79. 3-acetyl-5-[1-(4-hydroxy)piperidinyl]-5-phenyl-barbituric acid 80. S-[1-{4-methoxy)piperidinyl]-5-phenyl-2-thio-barbituric acid 81. 2-imino-5-[1-(4-methoxy)piperidinyl]-5-phenyl-barbituric acid 82. 5-[1-(4-methoxy)piperidinyl]-S-phenyl-2,4,6-triimino-barbituric acid 83. 4,6-diimino-5-[I-(4-methoxy)piperidinyl]-5-phenyl-barbituric acid 84. 5-[1-{4-methoxy)piperidinyl]-5-phenyl-2,4,6-trithio-barbituric acid 8S. 5-(6-aminohexyl}-S-[N-(2-hydroxyethyl)piperazinyl]barbituric acid 86. 5-{6-formylaminohexyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid 87. 5-{6-acetylaminohexyl}-S-[N-(2-hydroxyethyl)piperazinyl]barbituric acid 88. S-j7-(ethoxycarbonyl}heptyl]-S-[N-(2-hydroxyethyl)piperazinyl]barbituric acid 89. S-(8-hydro:~yoctyl)-5-[N-(2-hydroxyethyi)piperazinyl]barbituric acid 90. S-(7-carboxyheptyl)-5-[N-{2-hydroxyethyl)piperazinyl]barbituric acid 9I. S-[7-(aminocarbonyl)heptyl]-S-[N-{2-hydroxyethyl)piperazinyl]barbituric acid 3 0 92. 5-[3-((aminocarbonylmethyl)aminocarbonyl)propyl]-S-[N-(2-hydroxyethyl)-piperazinyl]barbituric acid 93. S-[6-(methylamino)hexyl]-S-[N-(4-nitrophenyl)piperazinyl]barbituric acid 94. S-[4-(n-propyloxy)butyl]-S-[N-(4-nitrophenyl)piperazinyl]barbituric acid 95. 5-[2-{2-(2-methoxyethoxy)ethoxy)ethyl]-S-[N-(4-3 5 nitrophenyl)piperazinyl]barbituric acid 96. 5-[2-(2-(ethoxy)ethoxy)ethyl]-5-[N-(4-nitrophenyi)piperazinyl]barbituric acid 97. S-decyl-5-[N-(4-nitrophenyi)piperazinyl]barbituric acid WO 97/23465 PCTlEP96/05766 98. 5-octyl-5-[N-(4-(hydroxysulphonyl)phenyl)piperazinyl]barbituric acid 99. 5-octyl-5-[N-(4-(aminosulphonyl)phenyl)piperazinyl]barbituric acid 100. 5-octyl-5-[N-(4-cyanophenyl}piperazinyl]barbituric acid ' 101. 5-octyl-5-[N-(4-carboxyphenyl)piperazinyl]barbituric acid 102. 5-octyl-5-[N-(4-(buthoxycarbonyl)phenyl)piperazinyl]barbituric acid 103. S-octyl-5-[N-(4-(amidino)phenyl)piperazinyl]barbituric acid 104. 5-octyl-5-[N-(4-(aminothiocarbonyl)phenyl)piperazinyl]barbituric acid 105. 5-octyl-5-[N-{4-(methylsulphonyl)phenyi)piperazinyl]barbituric acid 106. 5-octyl-5-[N-(4-(aminocarbonyl)phenyl)piperazinyl]barbituric acid 107. 5-octyl-5-jN-(4-{methylcarbonyl)phenyl)piperazinyl]barbituric acid 108. 5-octyl-5-[N-{4-(dimethylphosphonyl}phenyl)piperazinyl]barbituric acid 109. 5-octyl-5-[N-(4-(amino)phenyl)piperazinyl]barbituric acid 110. 5-octyi-5-jN-(4-{acetylamino)phenyl)piperazinyl]barbituric acid 1 i 1. 5-octyl-5-[N-(4-(trifluoroacetyiamino)phenyl}piperazinyl]barbituric acid 112. S-octyl-5-[N-(4-(methylsulphonylamino)phenyl)piperazinyl]barbituric acid 113. 5-octyl-5-[N-{5-nitropyrid-2-yI)piperazinyl]barbituric acid 114. 5-octyl-5-[N-{N-oxypyrid-4-yl)piperazinyl]barbituric acid 115. 5-octyl-5-[N-(4-(5-triazolyl)phenyl)piperazinyl]barbituric acid 116. 5-octyl-5-[(N-benzoyl-N-benzyl)amino]barbituric acid 2 0 117. 5-[4-(phenyl)phenyl]-5-j(N-benzoyl-N-benzyl)amino]barbituric acid 118. S-(4-[4-Nitrophenyl)piperazinyl])-5-octyl-barbituric acid 119. N-Benzyl-3-(4-nitro-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-S-yl)-acrylamide 120. 5-[4-(phenyl)phenyl]-5-[(N-benzoyl-N-benzyl)amino]-barbituric acid 121. N-Benzyl-2-(3-bromo-phenyl)-N-{2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acetamide Ezample 1 5-(1-f4-(2-H~xyethyl)piperazinyll)-5-phenyl-barbituric acid 5-Bromo-5-phenyl barbituric acid (Acta Chim. Acad. Sci. Hung. 107 139-45 (1981)) (7 mmol) and N-(2-hydroxy-ethyl)-piperazine (8 mmol) are suspended in 40 ml absolute ethanol. After 3 hours under reflux it is concentrated in a vacuum. The residue is purified by chromatography on silica gel (ethyl acetate/methanol 3 :1 ). Colourless crystals are obtained by recrystallization from isopropanol. Yield 56 %; Fp. 238-40°C (decomp.).

Example 2 S-(1-f4~-(4-Methylphenyl methyllpiperaziny,,-S-phenyl-barbituric acid ' S-Bromo-S-phenyl-barbituric acid (7 mmol) and N-(methyl-p-tolyl)-piperazin (8 mmol) are suspended in 40 ml absolute ethanol. After 2 hours under reflux it is concentrated in a vacuum. The residue is triturated with diethyl ether, sucked ofd rewashed with 20 ml diethyl ether and dried. The crude product is purified by chromatography on silica gel (acetone). One obtains colourless crystals. Yield 72 %; Fp. 247-48°C.
Example 3 ~1-I[4-(4-(4-Meth~Iphenyl))butyll~aerazin~l-5-phenyl-barbituric acid _.
4-(p-Tolyl)-butyl bromide The compound is prepared analogously to the literature. Synth. Commun.
22(20}2945-8 ( 1992). Yield 91 % colourless oil.
Phenyl-(4-{p-tolyl)-butyl)-malonic acid diethyl ester Phenylmalonic acid diethyl ester (8.8 mmol) dissolved in S ml absolute tetrahydrofuran is 2 0 added dropwise to 20 ml absolute tetrahydrofuran and sodium hydride (9.7 mmoI). Then 4-p-tolylbutyl bromide (8.8 mmol) dissolved in 10 ml absolute tetrahydrofuran is added after 1 S minutes. It is heated for 3 days under reflux. The solvent is concentrated in a vacuum. The residue is taken up in SO ml ethyl acetate and extracted with 2 x SO ml water. The organic phase is dried over magnesium sulfate, filtered and concentrated by 2 5 evaporation. It is purified by chromatography on silica gel (heptane/ethyl acetate 9:1 ).
Yield SS % colourless oil.
S-1-f4-(4-(4-meth ly phen~ 1)i )butyllpinerazinyl)-5=phenyl-barbituric acid Urea (4.6 mmol) and phenyl-(4-(p-tolyl)-butyt)-malonic acid diethyl ester (3.1 mmol) are 3 0 added to a solution of sodium ethylate (6.2 mmol) in absolute ethanol. It is heated for 12 hours under reflux, then concentrated in a vacuum and the residue is taken up in 1 S ml water. The mixture is adjusted to pH 1-2 with 6 N hydrochloric acid and extracted with 2 x 30 ml ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and concentrated by evaporation. The residue is purified by chromatography on silica gel 3 5 (heptane/ethyl acetate 3 :1 ). Yield 46 % colourless crystals; Fp. 163-S°C.

Example 4 S-( 1-(4-(2-Hydrox~yl)~peridinyll -5-phenyl-barbituric acid 14.6 g {50 mmol) phenylmalonic acid diethyl ester and subsequently 10 g (166 mmol) urea are slowly added to I .3 g sodium in 40 ml methanol while stirring. It is heated for 2 hours while slightly boiling. In this process a precipitate forms. It is cooled to 10-IS°C, subsequently slowly admixed with I 2.9 g { 100 mmol) 4-(2-hydroxyethyl)piperidine, 13.8 g ( I 00 mmol) potassium carbonate and 2.87 ml ( I I2.3 mmol) bromine. The mixture is stirred for 2 hours at 10-15°C, then slowly heated to boiling and boiled for 1 hour under reflux. After cooling it is poured onto 240 ml In nitric acid, the solution is washed once with toluene and neutralized with a saturated sodium acetate solution. A
greasy mass precipitates which is taken up in hot ethanol. The hot solution is treated with active carbon and admixed with warm water until turbidity starts. After cooling the crystals are suction filtered. Yield: 7.3 g = 44 %; Fp.: 222-223°C.
Example 5 S-Phenyl-5-(1=piperidinyl)barbituric acid 5-Phenyl-5-( I-piperidinyl)barbituric acid in a yield of 92 %; Fp.: 244-246°C is obtained analogously to example 4 using piperidine instead of 4-(2-hydroxyethyl) piperidine.
2 o Example 6 5-(1-(4-Hydroxy)~ eridinyl]-5-phenyl-barbituric acid _ __ 5-[I-(4-Hydroxy)piperidinyI]-5-phenyl-barbituric acid in a yield of39 %; Fp.:
241-242°C
(from ethanol) is obtained analogously to example 4 using 4-hydroxy-piperidine instead of 4-(2-hydroxyethyi)piperidine.
Example 7 5-[1-(4 4-Dirnethyl~p~eridin~l-5-phenyl-barbituric acid __ 5-[1-(4,4-Dimethyl)piperidinyl]-5-phenyl-barbituric acid in a yield of 69 %;
Fp.: 238-240°C (from ethanol/water) is obtained analogously to example 4 using 4,4-dimethyl-3 0 piperidine instead of 4-(2-hydroxyethyl)piperidine.
Example 8 5-jl-(4-Methyl)-piperidinyil-5-phenyl-barbituric acid 5-[ 1-{4-Methyl)piperidinyl]-5-phenyl-barbituric acid in a yield of 87 %; Fp.:
208-209°C
(from methanol/water} is obtained analogously to example 4 using 4-methyl-piperidine instead of 4-(2-hydroxyethyi)piperidine.

Example 9 5-f 1-(4-Methoxy)piperidinyll-5-phenyl-barbituric acid 5-[1-{4-Methoxy)piperidinyi]-5-phenyl-barbituric acid in a yield of 67 %; Fp.:
184-185°C
(from ethanol/water) is obtained analogously to example 4 using 4-methoxy-piperidine instead of 4-(2-hydroxyethyl) piperidine.
Example 10 5-Ethyl-5-f 1-(4-methyl piperidinyllbarbituric acid 14.1 g (75 mmol) ethylmalonic acid diethyl ester and subsequently 15 g (264 mmol) urea is slowly added to 1.95 g sodium in 60 ml methanol while stirring. After boiling for 2 hours a precipitate forms. It is cooled to 10-15°C and successively slowly admixed with g (15 mmol) 4-methylpiperidine, 21 g {150 mmol) potassium carbonate and 4.3 nnl ( I 68 mmol) bromine. The mixture is stirred for 2 hours at this temperature, slowly heated to boiling and heated for 1 hour under reflux. After cooling it is poured onto 360 15 ml 1 N nitric acid, the solution is washed once with toluene and admixed with an excess of saturated sodium acetate solution. The precipitated precipitate is recrystalIized from ethanol with addition of active carbon. Yield: 4.4 g = 23 %; Fp.: 194-195°C.
Example 11 2 0 5-Ethyl-5-'[ 1-(4-methoxy)piperidinyl~barbituric acid 5-Ethyl-5-[ I-{4-methoxy)piperidinyi]barbituric acid in a yield of 15 %; Fp.:
201-202°C
(from ethanol) is obtained analogously to example 10 using 4-methoxypiperidine instead of 4-methyipiperidine.
Example i2 5-Etl~l-5-(1-(4-h dy roxy~piperidinyl]barbituric acid 5-Ethyl-5-{I-(4-hydroxy)piperidinyl]barbituric acid in a yield of 5 %; Fp.: 1 IO-112°C
(from ethanol) is obtained analogously to example 10 when using 4-hydroxypiperidine instead of 4-methoxypiperidine.
Example 13 5-Ethyl-5-[~4-(2-hydroxyeth~)piperidinyl)]barbituric acid _ 5-Ethyl-5-[1-(4-(2-hydroxyethyi)piperidinyl)]barbituric acid in a yield of 17 %; Fp.: 238-240°C (from methanol) is obtained analogously to example 10 using 4-(2-3 5 hydroxyethyl)piperidine instead of 4-methylpiperidine.

Example 14 ~4-methox~phenyl)-5-[N-(2-hydroxvethyl)piperazinyl]barbituric acid a) preparation of ethyl 4-methoxyphenylacetate A solution of 4-methoxyphenylacetic acid (2 g) and para-toluensulfonic acid (230 mg) in 30 ml of ethanol is refluxed for 2 hours. The solvent is evaporated under reduced pressure and the residue is suspended in a saturated aqueous solution of sodium hydrogencarbonate and extracted twice with ethyl acetate. The organic extracts are collected, washed with water and dried over sodium sulfate to give, after evaporation of the solvent under reduced pressure, 2.14 g of the product.
b) preparation of ethyl 4-methoxyphenyl malonate A mixture of ethyl 4-methoxyphenylacetate (27.8 g) and sodium (3.68 g) in 90 ml of diethyicarbonate is refluxed for 3 hours, then the solvent is evaporated under reduced pressure and the residue is diluted with water and neutralized with acetic acid. The aqueous phase is extracted twice with diethyl ether. The organic extracts are pooled and washed twice with 1 N sodium hydroxide and once with water, then the organic phase is dried over sodium sulfate and concentrated to dryness. 34.2 g of the product are obtained.
c) preparation of 5-(4-methoxyphenyl)barbituric acid To a solution of 660 mg of sodium in 50 ml of ethanol are added 3.86 g of ethyl 4-methoxyphenyl malonate and 1.28 g of urea. The reaction mixture is refluxed far 3 hours. A white solid separates, which is collected by filtration and redissolved in 15 ml of water. The solution is acidified to pH = 1-2 by adding 6 N hydrochloric acid.
A white solid separates, which is filtered and washed on the filter with water. After drying under vacuum at 50°C for several hours, 2.28 g of the product are obtained.
d) preparation of 5-bromo-5-(4-methoxyphenyl)barbituric acid 3 0 To a suspension of 5-(4-methoxyphenyl)barbituric acid (222 mg) in 3 mi of water, cooled to 0-5°C with ice bath, are added 136 p.l of 48% hydrobromic acid and 56 p.I of bromine, dropwise. After 1 hour at a temperature below 10°C, the solid which separated is collected by filtration and washed on the filter with water. The solid is dried for several hours under vacuum at 50°C, to give 283 mg of the product.

e) preparation of the title compound A solution of 5-bromo-5-(4-methoxyphenyl)barbituric acid ( 1 I .5 g) and N-(2-hydroxyethyl) piperazine ( I 5.755 g) in 260 ml of methanol is refluxed for about 2 hours, then the solid which separated is collected by filtration, redissolved in 100 ml of methanol and heated at reflux for I hour. The solid is filtered again and dried at 80°C
under vacuum to give 9 g of the product containing 8-9% of methanol. The solid is dissolved in 40 ml of 1 N hydrochloric acid, then the solution is basified with 3.42 g of sodium hydrogencarbonate and cooled at 0-5°C for 4 hours. The product is recovered by filtration and it is dried under vacuum at 80°C for sevaral hours, to give 8.55 g of the pure product, m.p. 247-248°C.
'H-NMR in d6-DMSO: 2.36 ppm (m, 6H); 2.55 ppm (m, 4H); 3.44 ppm (q, ZH); 3.74 ppm (s, 3H); 4.33 ppm (t, I H); 6.95 ppm (d, 2H); 7.3 ppm (d, 2H); 11.54 ppm (br s, 2H).
Example 15 5-[3-(4-methoxyphenyl)propyl]-5-[4-(2-hydroxyethyl)piperazinyl] barbituric acid a) preparation of 3-(4-methoxyphenyl)propionyl chloride 2 0 To a suspension of 3-(4-methoxyphenyl)propioruc acid ( 10 g) in 150 ml of toluene are added 8 ml of thionyl chloride and the mixture is heated to 65°C for 4 hours. The solvent is evaporated off under reduced pressure and the residue is redissolved in toluene and concentrated to dryness. Such steo is repeated twice. 11 g of the product are obtained as a yellow oil.
b) preparation of 5-{3-(4-methoxyphenyi)propionyl]barbituric acid To a suspension of barbituric acid (6.4 g) in 48 mi of pyridine are added dropwise 11 g of 3-(4-methoxyphenyl)propionyl chloride and the mixture is stirred at room temperature 3 0 for 18 hours. The reaction mixture is then poured into ice and acidified to pH = 1 by adding 6 N hydrochloric acid. A solid precipitates, which is filtered and resuspended in methanol. The suspension is kept under stirring for 15 minutes, then the solid is recovered by filtration to give 12.2 g of the product. m.p. 248-250°C.

c) preparation of 5-[3-(4-methoxyphenyl)propyl]barbituric acid To a suspension of 10 g of 5-[3-(4-methoxyphenyl)propionyl]barbituric acid in 100 ml of acetic acid are added portionwise 4.5 g of sodium cyanoborohydride, then the mixture is heated to 60°C. After 1 hour the reaction mixture is cooled to room temperature and poured into ice. After 30 minutes a solid is recovered by filtration, which is dried under vacuum at 50°C to give 8.74 g ofthe product, m.p. 195-197°C.
d) preparation of 5-bromo-5-[3-(4-methoxyphenyl)propyl]barbituric acid A mixture of 5-[3-(4-methoxyphenyl)propyt]barbituric acid (2.5 g), N-bromosuccinimide {2 g) and dibenzoyl peroxide (catalytic amount) in I 10 ml of carbon tetrachloride is refluxed for about 1 hour, then the solid which separated is filtered. The solid is redissolved in ethyl acetate and filtered through a silica gel cake in order to eliminate the succinimide residue. The organic phase is then concentrated to dryness and the residue is crystallized from diethylether/carbon tetrachloride mixture. A pale yellow solid separates which is filtered and dried under vacuum at 60°C to give 2.8 g of the product, m.p. 1 I3-114°C.
e} preparation ofthe title compound A mixture of 5-bromo-5-[3-(4-methoxyphenyl)propyl]barbituric acid (710 mg) and N-(2-hydroxyethyl}piperazine (281 mg) in ZS mI of ethanol is refluxed for 4 hours.
The solvent is evaporated under reduced pressure and the residue is partitioned between 1 N
hydrochloric acid and ethyl acetate. The aqueous phase is basified to pH =6-7 and extracted with ethyl acetate. The organic phase is concentrated to dryness and the residue is crystallized from ethyl acetate to give 30 mg of the product.
'H-NMR in d6-DMSO: 1.32 ppm (m, 2H); 1.86 ppm (m, ZH); 2.33 ppm (m, 6H); 2.45 ppm (m, 2H); 2.53 ppm (m, 4H); 3.43 ppm (q, 2H); 3.7 ppm (s, 3H); 4.35 ppm (t, 1H);
3 0 6.8 ppm (d, 2H); 7.04 ppm (d, 2H); I 1.53 ppm {br s, 2H).
Example 16 5-phen~-[4-(2-hvdroxyethylidene~piperidin~lbarbituric acid a) preparation of 4-(ethoxycarbonylmethyiidene)piperidine To a suspension of sodium hydride (2.6 g) in 30 ml oftetrahydrofuran, cooled to 0°C
and kept under nitrogen atmosphere, 13 ml of triethylphosphonoacetate, dissolved in I 0 ml of tetrahydrofuran, are added dropwise. The temperature is then brought to room temperature and the stirring is continued for 30 minutes. The mixture is again cooled to 0°C and it is added dropwise with a solution obtained by adding portionwise to a solution of 4-piperidone monohydrate hydrochloride ( 10 g) in THF 2.6 g of sodium hydride. filtered to eliminate the sodium chloride which formed. At the end of the addition, the temperature is brought to room temperature and the stirring is continued for 20 hours. The solvent is then evaporated under reduced pressure and the residue is redissolved in ethyl acetate and washed with I N hydrochloric acid. The aqueous phase is extracted with ethyl acetate and chloroform, then it is basified to pH = 9-10 by adding 20% sodium hydroxide and it is extractedb with chloroform. The aqueous phase is then salted and extracted again with chloroform three times. The pooled extracts are dried over sodium sulfate and evaporated to give 7.1 g of the product as a yellow oil.
b) preparation of 4-(hydroxyethylidene)piperidine A solution of I 5 ml of DIBAL ( 1.5 M solution in toluene) in 20 ml of toluene is added dropwise with 0.976 g of 4-(ethoxycarbonyimethylidene)piperidine, dissolved in few milliliter of toluene. The reaction mixture is stirred at room temperature for 2 hours, then it is cooled to 0-5°C and added dropwise with methanol, until the gaz development is seen. The mixture is concentrated to a little volume and diethyl ether is added: a white solid separates, which is filtered ofl' The organic phase is concentrated to dryness, 2 0 redissolved in diethyl ether and again filtered. The clear solution is concentrated to dryness to give 500 mg of the product.
c) preparation of the title compound A mixture of 5-bromo-5-phenylbarbituric acid (2.45 g), 4-(hydroxyethylidene)piperidine 2 5 ( 1.053 g) and triethylamine { 1.15 mI) in 50 ml of ethanol is refluxed for 2 hours. The solvent is evaporated under reduced pressure and the residue is purified by silica gel chromatography (40 g; eluent: ethyl acetate/petroleum ether 8:2), to give 450 mg of the product.
1H-NMR in d6-DMSO: 2.13 ppm {m, 4H); 2.55 ppm (m, 4H); 3.89 ppm (d, 2H); 4.46 30 ppm (br s, 1H); 5.24 ppm (t, IH); 7.42 ppm (m, SH); 11.6 ppm (br s, 2H).
50 mg of 5-phenyl-5-[4-(2-hydroxyethyl)-1,2,5,6-tetrahydropyridinyl]barbituric acid as a side product are also recovered.
1H-1'JMR in d6-DMSO: 1.96 ppm (m, 2H); 2.09 ppm (t, 2H); 2.64 ppm (t, 2H);
3.00 35 ppm {m, 2H); 3.47 ppm (q, 2H); 4.43 ppm (t, IH); 5.3 ppm (m, 1H); 7.4 ppm (s, SH);
11.63 ppm {br s, 2H).

Example 17 5-phenyl-5-jN-(2-hydroxyethyl)~perazin~l-2-thiobarbituric acid a) preparation of diethyl 2-bromo-2-phenylmalonate To a solution of diethyl 2-phenylmalonate ( 15 mI) in 200 ml of tetrahydrofuran, kept at 0°C and under nitrogen atmosphere, 3.475 g of sodium hydride are added and the mixture is kept 30 minutes under stirring at 0°C, then it is brought to room temperature.
After cooling again to 0°C, the reaction mixture is added with 14.3 g of N-bromosuccinimide. After about 15 minutes, the white solid which separated is filtered off and the filtrate is concentrated to dryness to give a residue which is redissolved in chloroform and dried over sodium sulfate. The solvent is evaporated under reduced pressure to give 15.66 g of the product.
b) preparation of diethyl 2-phenyl-2-[4-(2-hydroxyethyl)piperazinyl]malonate A solution of diethyl 2-bromo-2-phenylmalonate ( 16.8 g) in I 50 ml of dimethylsulfoxide is heated to 90-100°C, then N-(2-hydroxyethyl)piperazine (27.9 g) is added and the reaction mixture is heated for additional 4 hours. The mixture is poured into water and extracted with ethyl acetate three times. The pooled organic extracts are washed with 1 N hydrochloric acid. The aqueous phase is basified with 1 N sodium hydroxide to pH =
2 0 8-9 and it is extracted twice with ethyl acetate. The organic extracts are collected and are washed with a saturated aqueous solution of sodium chloride and dried over sodium sulfate. After removal of the solvent under reduced pressure, the residue is crystallized from diethylether/petroleum ether 1:1 to give 6.5 g of the product, m.p. 63-64°C.
2 5 c) preparation of the title compound To a solution of sodium (27 mg) in 3 ml of ethanol are added 218 mg of diethyl phenyl-2-[4-(2-hydroxyethyl)piperazinyl]malonate and 288 mg of thiourea, then the mixture is refluxed for about 13 hours. The reaction mixture is cooled to room temperature and 140 p.l of acetic acid are added, then the solvent is evaporated under 3 0 reduced pressure. The residue is redissolved in a ethyl acetatelmethanol 9:1 mixture. The solid which separates is filtered off and the filtrate is concentrated to dryness and purified by silica gel chromatography (eluent: from ethyl acetate to ethyl acetate/methanol 9:1 ), to give, after crystallization from ethyl acetate, 30 mg of the product, m.p.
>250°C.
35 1H-NMR in d6-DMSO: 2.4 ppm (m, 6H); 2.59 ppm (m, 4H); 3.46 ppm (q, 2H); 4.4 ppm (t, 1H); 7.4 ppm (m, SH); 12.5 ppm (br s, 2H).

Example 18 5-phenyl-5-[N-(2-hvdroxyeth~)piperazinyl]-2-azobarbituric acid To a solution of sodium (70 mg) in 5 ml of ethanol are added 218 mg of diethyl phenyl-2-[4-(2-hydroxyethyl)piperazinyl]malonate (example 4 - step b) and 172 mg guanidine hydrochloride and the mixture is refluxed for 8 hours. Further 57 mg of guanidine hydrochloride are added and the mixture is refluxed for additional 6 hours. The temperature is brought to room temperature and acetic acid is added until neutralization occurs, then the solid which is formed is filtered ofd The filtrate is concentrated to dryness and redissolved in ethanol, from which by adding of ethyl acetate a solid separates. After 1 hour at -4°C the white solid is recovered by filtration and it is recrystallized from methanol (2 ml), to give, after drying under vacuum at 90°C for 4 hours, 78 mg of the product, m.p. >250°C.
1H-NMR in d6-I~M50: 2.33 ppm (m, 6H); 2.54 ppm (m, 4H); 3.41 ppm (t, ZH); 4.33 ppm (br s, 1H); 7.00 ppm (br s, 1H); 7.33 ppm (m, SH); 7.5 ppm (br s, 1H); l I.4 ppm (br s, 1H).
Example 19 2 0 5-benzyl-5-fN-(2-hvdroxyeth~~~erazinyl]barbituric acid -a) preparation of 5-benzylidenebarbituric A suspension of 5 g of barbituric acid in 50 ml of water is heated until a compklete dissolution occurs, then it is added with 4.3 ml of benzaldheide. The mixture is refluxed for 1 hour, then the solid which separated is filtered, washed several times with water and dried under vacuum at 100°C, to give 8. I7 g of the product, m.p.
>258°C.
b) preparation of 5-benzylbarbituric acid To a suspension of 5-benzylidenebarbituric acid (4 g) in 200 ml of methanol are added portionwise 1.4 g of sodium borohydride. After 10 minutes from the end of the addition, 3 0 100 ml of water are added and the mixture is acidified with 1 N
hydrochloric acid to pH
= 2. The solvent is evaporated off and the aqueous phase is extracted with ethyl acetate.
The pooled extracts are dried over sodium sulfate and concentrated to dryness.
3.6 g of the product crystallize, m.p. 207-209°C.
3 5 c) preparation of 5-bromo-5-benzylbarbituric acid To a suspension of 5-benzylbarbituric acid (1.7 g) in 15 ml of water, cooled to 0-5°C, I
ml of 48% hydrobromic acid are added, followed by the addition dropwise of 0.437 ml of bromine into the reaction mixture. After 1 hour under stirring at a temperature below 10°C. the solid which formed is separated by filtration and washed with water. 2.17 g of the product are obtained. m.p. 164-166°C.
d) preparation of the title compound A solution of S-bromo-S-benzylbarbituric acid (2.15 g) and N-(2-hydroxyethyl)piperazine in 50 ml of ethanol is refluxed for 4 hours, then it is cooled to room temperature and added with 4 ml of triethylamine. The solvent is evaporated off and the white residue is redissolved in a ethyl acetate/methanol 3:1 mixture.
An ornage solid crystallizes, which is recovered by filtration. After recrystallization from ethanol 0.62 g of the product are obtained, m.p. 243-246°C.
tH-NMR in d6-DMSO: 2.43 ppm (t, 2H); 2.58 ppm (m, 4H); 3.03 ppm (m, 4H); 3.34 ppm (s, 2H); 3.49 ppm (q, 2H); 4.5 ppm (t, 1H); 7.13 ppm (m, SH); 8.8 ppm (br s, 2H).
Example 20 S-[N-(2-hydrox~~piperazin lei-5-(4-h d~ roxXphenyl)barbituric acid a) preparation of 5-(4-hydroxyphenyl)barbituric acid To a suspension of S-(4-methoxyphenyl)barbituric acid (222 mg) in S ml of methylene .
2 0 chloride, kept at -S/-10°C and under nitrogen atmosphere, is dropped a solution of boron tribromide (473 p.I) in 2 ml of methylene chloride. The stirring is continued for additional 2 hours at -5°C, then the temperature is brought to room temperature and stirnng is continued for further 20 hours. The reaction mixture is again cooled to 0°C with an ice bath and it is basified to pH = 9-10 by adding dropwise 5% sodium hydroxide.
The aqueous phase is separated, filtered through a celite plug, cooled with ice bath and acidified to pH = 1 with 37% hydrochloric acid. A white solid separates which after 1 hour is separated by filtration and dried under vacuum at 60°C to give 215 mg of the product.
3 0 b) preparation of 5-[4-(tertbutyldimethylsilyloxy)phenyl]barbituric acid To a solution of 5-(4-hydroxyphenyl)barbituric acid (1.9 g) and tertbutyl dimethylsilyl chloride (4.68 g) in 20 ml of anhydrous dimethylformamide are added 4.4 g of imidazole and the mixture is heated to 55°C for 5 hours. The temperature is then brought to room temperature and the reaction mixture is poured into 1 N hydrochloric acid and extracted 3 5 twice with ethyl acetate. The pooled organic extracts are washed with water and dried over sodium sulfate. By concentration of the solution a white solid separates, which is kept at 0°C overnight, then it is filtered to give 2.185 g of the product.

c) prepay anon of 5-bromo-5-[(4-tertbutyldimethylsilyloxy)phenyl]barbituric acid To a suspension of 5-[4-{tertbutyldimethylsilyloxy)phenyl]barbituric acid (330 mg) and dibenzoyl peroxide (catalytic amount) in 10 ml of carbon tetrachloride are added 210 mg of N-bromosuccinimide. The mixture is stirred at room temperature for 1 hour, then the solvent is evaporated off and the residue is purified by silica gel chromatography (eluent:
petroleum ether/ethyl acetate 8:2), to give 260 mg of the product.
d) preparation of 5-[N-(2-hydroxyethyl)piperazinyl]-S-[(4-tertbutyldimethylsilyloxy}phenyl]barbituric acid A solution of 5-bromo-5-[(4-tertbutyldimethylsilyloxy)phenyl]barbituric acid (260 mg) and N-(2-hydroxyethyl)piperazine (98 mg) in 5 ml of ethanol is refluxed for 1 hour, then it is brought to room temperature and added with 0.3 ml of triethylamine. The solvent is evaporated off and the residue is purified by silica gel chromatography (25 g;
eluent:
ethyl acetate/methanol 3 :1 ), to give, after crystallization from ethyl acetate, 170 mg of the product, m.p. 220-221°C.
e) preparation of the title compound A mixture of 5-[N-(2-hydroxyethyl)piperazinyl]-5-[(4-tertbutyldimethylsilyloxy)phenyl]barbituric acid ( 148 mg), tetrabutylammonium fluoride 2 0 ( 1.1 M in THF; 0.6 ml) and acetic acid (290 pl) in 10 mi of tetrahydrofuran, kept at 0°C, is stin-ed for 2 hours 30 minutes, then the solvent is evaporated off and the residue is purified by silica gel chromatography ( 12 g; eluent: ethyl acetate/methanol 3 :1 ), to give, after crystallization from ethyl acetate and recrystailization from ethyl acetate/methanol mixture, 40 mg of the product, m.p. >25°C.
'H-NMIt in d6-DMSO: 2.37 ppm {m, 6H); 2.55 ppm (m, 4H); 3.45 ppm (q, 2H); 4.35 ppm (t, 1H); 6.76 ppm {d, ZH); 7.17 ppm (d, 2H); 9.72 ppm (s, iH); 11.47 ppm (br s, 2H).
Ezample 21 3 0 5-[N-(2-hydrox r~ eth~~perazinyll-5-(3-hydroxyphenyl)barbituric acid a) preparation of ethyl 3-hydroxyphenylacetate A suspension of 3-hydroxyphenylacetic acid {5.4 g) and para-toluensulfonic acid (650 mg) in 80 ml of ethanol is refluxed for 4 hours, then the solvent is evaporated off and the 3 5 residue is dissolved in ethyl acetate and washed twice with a saturated aqueous solution of sodium hydrogencarbonate. The organic phase is dried over sodium sulfate and the solvent is evaporated off to give 6.08 g of the product as a yellow oil.

b} preparation of ethyl 3-(tertbutyldimethylsilyioxy)phenylacetate To a solution of ethyl 3-hydroxyphenylacetate (6 g) and tertbutyldimethylsilyl chloride (6 g) in 80 ml of anhydrous dimethylformamide are added 5.66 g of imidazole and the mixture is stirred at room temperature for I hour 30 minutes. The reaction mixture is then poured into water and extracted twice with ethyl acetate. The pooled organic extracts are dried over sodium sulfate and concentrated to dryness to give 10 g of the product as a yellow oil.
c} preparation of diethyl 3-(tertbutyldimethylsilyloxy)phenylmalonate To a solution of ethyl 3-(tertbutyldimethylsilyloxy)phenylacetate ( 10 g) in 25 ml of diethyicarbonate are added portionwise 0.86 g of sodium and the mixture is refluxed for 2 hours. The solvent is evaporated off and the residue is poured into water (90 ml). The pH is adjusted to pH = 6 with acetic acid and the mixture is extracted with diethyl ether.
The organic phase is dried over sodium sulfate and cocentrated to dryness to give 10 g of an orange oil which is purified by silica gel chromatography (eluent:
petroleum ether/ethyl acetate 95:5}, to give 2.45 of the product.
d) preparation of 5-[3-(tertbutyldimethylsilyloxy)phenyl]barbituric acid To a solution of diethyl 3-(tertbutyldimethylsilyloxy)phenylmalonate ( I .5 g) in 1 S ml of 2 0 ethanol are added 0.445 g of sodium ethoxide and 0.295 g of urea and the mixture is refluxed for 3 hours. The reaction mixture is cooled to room temperature and the solid formed is filtered. The solid is redissolved in water, the pH is adjusted to pH = I-2 with 6 N hydrochloric acid and the soild which precipitates is recovered by filtration. The flitrate is concentrated to eliminate the ethanol, then the solution is basified and extracted 2 5 with ethyl acetate. The organic phase is concentrated to dryness to give 250 mg of residue which is pooled with the solid previously filtered (350 mg). The residue so obtained contains a mixture of the product along with the de-silyiated derivative.
Such a residue (550 mg) is dissolved in 5 ml of anhydrous dimethylformamide and 790 3 0 mg of tertbutyldimethylsilyl chloride and 745 mg of imidazole are successively added.
The mixture is heated to 55°C for 5 hours. Furher 75 mg of imidazole and 79 mg of tertbutyldimethylsily! chloride are added and the heating is continued for an additional hour. The reaction mixture is then poured into 1 N hydrochloric acid and extracted three times with ethyl acetate. The pooled organic extracts are washed with water and dried 3 5 over sodium sulfate. The solution is concentrated and a white solid precipitates. 710 mg of the product are recovered by filtration.

e) preparation of 5-[3-(tertbutyldimethylsilyloxy)phenyl]-5-bromobarbituric acid A mixture of S-[3-(tertbutyldimethylsilyloxy)phenyl]barbituric acid (680 mg), N-bromosuccinimide (432 mg) and dibenzoyl peroxide (catalytic amount) in 10 ml of carbon tetrachloride are stirred at room temperature for 1 hour. The solvent is evaporated off and the residue is purified by silica gel chromatography (eluent: ethyl acetate/hexane 7:3) to give 550 mg ofthe product, m.p. 170-I72°C.
~ preparation of S-[N-(2-hydroxyethyl)piperazinyl]-S-[3-(tertbutyldimethylsilyloxy)phenyl]barbituric acid A solution of 5-[3-(tertbutyldimethylsilyloxy)phenylj-5-bromobarbituric acid (444 mg) and N-(2-hydroxyethyl)piperazine (420 mg) in 10 ml of methanol is stirred at room temperature for 5 hours, then the solvent is evaporated ofd and the residue is purified by silica gel chromatography ( 13 g; eluent: ethyl acetate/methanol 3:1), to give 70 mg of the product.

g) preparation of the title compound To a solution of 5-[N-{2-hydroxyethyl)piperazinyl]-5-[3-(tertbutyldimethyisilyloxy)phenyl]barbituric acid (170 mg) in I2 ml of tetrahydrofuran, kept at 0°C and under nitrogen atmosphere, are added 333 p.l of acetic acid and 0.69 ml 2 0 of tetrabutylammonium fluoride. The mixture is stirred for 3 hours then the solvent is evaporated off and the residue is purified by silica gel chromatography { I 5 g; eluent:
ethyl acetate/methanol 4:1 ), to give, after crystallization from methanol, 3 S mg of the product, m.p. 219-221 °C.
1H-NMR in d6-DMSO: 2.37 ppm (m, 6H}; 2.59 ppm (m, 4H); 3.45 ppm (q, 2H); 4.35 25 ppm (t, 1H); 6.74 ppm (m, 2H); 6.92 ppm (t, IH}; 7.18 ppm (t, 1H); 9.62 ppm (s, IH);
1 I.54 ppm (br s, 2H).
Example 22 5-LTl-(2-hydroxyeth r~l piperazinyl]-5-(4-methylt~henyl~barbituric acid a) preparation of S-(4-methylphenyl)barbituric acid To a solution of sodium ( I 84 mg) in I 2 mI of ethanol are added 0.95 ml of diethyl 2-(4-methylphenyl)malonate and 360 mg of urea. then the mixture is refluxed for 3 hours. A
white solid separates, which is filtered and redissolved in 4 ml of water. The solution is acidified to pH = 1-2 by adding 6 N hydrochloric acid. A white solid separates, which is collected by filtration, washed with I 5 ml of water and dried under vacuum.
619 mg of the product are obtained, m.p. 27I°C.

b) preparation of S-bromo-S-(4-methylphenyl)barbituric acid To a suspension of 5-(4-methylphenyl)barbituric acid (218 mg) in 2 ml of water, kept at I 0°C under stirring, I 36 p.I of 48% hydrobromic acid are added, then S6 p.l of brominr are dropped and the stirring is continued for 3 hours. The precipitate which formed is recovered by filtration and washed with water. then it is dried under vacuum to give 270 mg of the product, m.p. 210-213°C.
c) preparation of the title compound A solution of S-bromo-5-(4-methylphenyi)barbituric acid (3.1 g} and of N-(2-hydroxyethyl) piperazine ( I .S3 g) in 60 ml of ethanol is refluxed for 3 hours. The solvent is evaporated ofd' and the residue is dissolved in I N hydrochloric acid and washed twice with ethyl acetate, The aqueous phase is basified with 1 N sodium hydroxide and extracted with ethyl acetate. The organic extracts are concentrated to dryness and the residue is purified by silica gel chromatography ( i 00 g; eluent: ethyl acetate/methanol 3 :1 ), to give, after evaporation of the solvent, 1.97 g of the product as hydrobromide.
The free base is obtained by treating an ethyl acetate suspension (200 ml) of the salt with SO ml of a saturated aqueous solution of sodium hydrogencarbonate and by extraction of the aqueous phase with ethyl acetate. By concentrating to dryness the pooled organic 2 0 extracts 1. I 8 g of theproduct are obtained.
'H-NMR in d6-DMSO: 2.3 ppm (s, 3H); 2.35 ppm (m, 6I~; 2.57 ppm (m, 4H); 3.45 ppm (q, 2H); 4.35 ppm (t, IH); 7.19 ppm (d, ZH); 7.28 ppm (d, 2H); 1 I.SS ppm (br s, 2H).
Example 23 S-octyl-S-[N-(2-hydroxyethyl)piperazinyl]barbituric acid a) preparation of diethyl 2-octylmalonate 3 0 To a solution of 2.63 of sodium in 100 ml of ethanol is added dropwise a solution of 19. I ml of diethylmalonate in 10 ml of ethanol. The mixture is successively added with 20.4 ml of 1-bromooctane dissolved in 10 ml of ethanol, then the mixture is refluxed for 6 hours. The reaction mixture is concentrated to a little volume and the residue is partitioned between a saturated aqueous solution of sodium hydrogenphosphate (200 ml) 3 5 and ethyl acetate (200 ml). The organic phase is washed with 7S ml of water and 7S ml of saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated to dryness. to give 3 I .8 g of the product as an oil.

1H-NMR in CDCI3: 0.80-0.95 ppm (m. 3H); 1.15-1.40 ppm (m, 18H); 1.88 ppm (q, 2H); 3.33 ppm (t, 1H); 4.19 ppm (q, 4H).
b) preparation of 5-octylbarbituric acid To a solution of sodium (5.32 g) in 400 ml of anhydrous ethanol is added a solution of diethyl 2-octylmalonate (31.5 g) in 50 ml of ethanol and successively 10.27 g of urea, then the mixture is refluxed for 2 hours 30 minutes. The mixture is rapidly cooled to room temperature and the solid which was formed is recovered by filtration and washed with diethyl ether. The solid is then dissolved in 200 ml of water and acidified with 6 N
hydrochloric acid until pH I .5-2 is reached. A solid separates. The mixture is added with 200 ml of ethyl acetate and it is stirred for 2 hours, then it is added with additional 800 ml of warm ethyl acetate. The organic phase is separated and the aqueous phase is washed with 200 ml of ethyl acetate.The pooled organic phases are washed with 250 ml of saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated to dryness. 21.03 g of the product are obtained.
1H-NMR in d6-DMSO: 0.77-0.80 ppm (m, 3H); 1.23 ppm (s, 12H); 1.80-1.95 ppm {m, 2H); 3.52 ppm (t, 1H); 1 1.15 ppm (s, ZH).
c) preparation of 5-bromo-5-octylbarbituric acid 2 0 To a suspension of 5-octylbarbituric acid (20 g) in 120 ml of water, cooled at 0-5°C, are added 12 ml of 48% hydrobromic acid and successively are dropped 4.72 ml of bromine.
Ater 2 hours under stirring, the white solid which separated is recovered by f ltration, washed with water and partitioned between 200 ml of diethyl ether and 100 ml of water.
The aqueous phase is extracted with additional 50 ml of diethyl ether. The pooled 2 5 organic phases are washed with 75 ml of saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated to dryness. 25.8 g of the product as white solid are obtained.
IH-NMR in d6-DMSO: 0.78-0.90 ppm (m, 3H); 1.10-I.38 ppm (m, 12H); 2.20-2.34 ppm (m, 2H); 1 1.80 ppm (s, 2H).
d) preparation of the title compound To a solution of 5-bromo-5-octylbarbituric acid (23.52 g) in 70 ml of dimethylsulfoxide, kept under nitrogen atmosphere and at a temperature of 5-10°C, is dropped N-(2-hydroxyethyl}piperazine (36.2 ml), then the mixture is stirred at room temperature for 2 3 5 hours 30 minutes. The reaction mixture is poured into water ( 1 1) under stirring and cooling with an ice bath. The white solid which separates is recovered by filtration, WO 97!23465 PCT/EP96/05766 washed with water and dried under vacuum at 40°C, to give, after crystallization from ethanol { 140 ml) I 0.91 g of the product as a white solid, m.p. 183-184°C.
1H-NMR in d6-DMSO: 0.75-0.88 ppm {m, 3H); 0.90-1.10 ppm (m, 2H); 1.12-1.30 ppm (m, lOH); 1.75-1.90 ppm (m, 2H); 2.23-2.40 ppm (m, 6H); 2.45-2.60 ppm (m, 4H);
3.45 ppm (br t, 2H); 4.35 ppm (br s, 1H); I 1.55 ppm (s, 2H).
Example 24 5-naphtyl-5- ~2-h~yeth~)piperazinyllbarhituric acid a) preparation of ethyl 2-naphtylacetate To a solution of 2-naphtylacetic acid {5 g} in 50 ml of ethanol are added 0.5 g of para-toluensulfonic acid, then the reaction mixture is refluxed for about 4 hours.
The solvent is evaporated off and the residue is dissolved in diethyl ether, washed twice with a saturated aqueous solution of sodium hydrogencarbonate and once with brine, then the pooled organic extracts are dried over sodium sulfate and concentrated to dryness. 5.64 g of the product as a yellow oil are obtained.
b) preparation of diethyl 2-naphtylmalonate 2 0 To a solution of ethyl 2-naphtylacetate (2 g) in 23.3 ml of diethylcarbonate, kept under stirring and at room temperature, are added portionwise 0.232 g of sodium. The reaction mixture is refluxed for 2 hours 30 minutes, then it is concentrated in order to eliminate the not reacted diethylcarbonate and it is added with 20 ml of cold water. The resulting mixture is acidified with acetic acid until weak acidity is reached, then it is extracted three times with diethyl ether. The pooled organic extracts are dried over sodium sulfate and the solvent is evaporated off, to give, after recrystallization from diethyl ether ( 19 ml), 1.0I S g of the product as a white solid.
c) preparation of 5-naphtylbarbituric acid 3 0 A solution of sodium (0.32 g) in 30 ml of anhydrous ethanol is added with diethyl 2-naphtylmalonate (2 g} and successively with urea (0.63 g). The mixture is refluxed for 2 hours, then the solid which separated is recovered by filtration, then it is dissolved in 7 ml of water and acidified to pH = 1 with 6 N hydrochloric acid. A white solid precipitates which, after 30 minutes under stirring, is filtered and washed with water. The 3 5 solid is dried overnight under vacuum at 40°C, to give 0.96 g of the product.

d} preparation of 5-bromo-5-naphtylbarbituric acid A suspension of 5-naphtylbarbituric acid (0.2 g) in 1.5 ml of 95% ethanol, cooled at 0°C
and kept under stirring, is added dropwise with 48% hydrobromic acid (0.5 ml) and successively with 4.4 pl of bromine. After 4 hours under stirring at room temperature the solid is filtered and washed with water, then it is dried under vacuum at 40°C overnight.
0.25 g of the product are obtained.
e) preparation of the title compound To a suspension of 5-bromo-5-naphtylbarbituric acid (0.24 g) in 3.5 mI of ethanol is added a solution of N-(2-hydroxyethyl)piperazione (0.1 I2 g) in 1.5 ml of ethanol. The reaction mixture is refluxed for 5 hours, then it is cooled to room temperature and the solid which separates is filtered off. The filtrate is added with 100 p.l of triethylamine, then the solvent is evaporated off to give 0.364 g of a solid, which is recrystallized from a mixture of methanoi (4.5 ml) and ethyl acetate (10 ml). The obtained solid (70 mg) is washed under stirring with an ethyl acetate/water mixture for 2 hours and dried under vacuum at 40°C for 8 hours, to give 60 mg of the product.
'H-NMR in d6-DMSO: 2.3-2.5 ppm (m, 6H); 2.6 ppm (m, 4H); 3.45 ppm (m, ZH);
4.35 ppm (t, 1 H); 7.4-8. I ppm (m, 7H); 11.65 ppm (s, 2H).
2 0 Example 25 5-(4'-biphenyl)-5-!Tt-(2-hydrox~yl)piperazinyl]barhituric acid a) preparation of ethyl (4'-biphenyl)acetate A suspension of (4'-biphenyl)acetic acid (6.4 g) in 60 ml of ethanol is added with 1.1 g of para-toluensulfonic acid. then the reaction mixture is refluxed for 4 hours 30 minutes.
The solvent is evaporated ofd the residue is dissolved in diethyl ether and the resulting organic phase is washed three times with a saturated aqueous solution of sodium hydrogencarbonate and once with brine. The organic phase is then dried over sodium sulfate and the solvent is evaporated off to give 7.1 g of the product as a yellow oil.
b) preparation of diethyl (4'-biphenyl)malonate A solution of ethyl (4'-biphenyl)acetate (7.1 g) in 60 m1 of diethylcarbonate, kept under nitrogen atmosphere, is added portionwise with sodium (0.734 g), then it is heated at I20°C for 3 hours. The solvent is evaporated off and the residue is dissolved in 65 mI of 3 5 cold water and acidified with acetic acid until pH = 5-6 is reached. The aqueous phase is then extracted three times with diethyl ether and the pooled organic extracts are dried over sodium sulfate and concentrated to dryness. The residue is purified by silica gel chromatography (eluent: petroleum ether/diethyl ether 9.4:0.6) to give 7.05 g of the product, m.p. 51-53°C.
c) preparation of 5-(4'-biphenyl)barbituric acid A solution of sodium (0.322 g) in 40 ml of anhydrous ethanol is added with diethyl (4'-biphenyI)malonate (2.2 g) and successively with urea (0.63 g). The reaction mixture is refluxed for 3 hours 30 minutes, then it is cooled to room temperature and the solid is recovered by filtration. The obtained solid is redissolved in 40 ml of warm water and the resulting aqueous phase is acidified to pH = 1 with 6 N hydrochloric acid. The solid which separates is kept I 5 minutes under stirnng, then it is filtered and dried under vacuum at 60°C. 1.1 g of the product are obtained, m.p. >240°C.
d) preparation of 5-bromo-5-{4'-biphenyl)barbituric acid A suspension of 5-(4'-biphenyl)harbituric acid (0.28 g) in 1.4 ml of water, cooled at 0°C
and kept under stirring, is added dropwise with 0.14 ml of 48% hydrobromic acid and successively with 55.5 p.l of bromine. The temperature is then brought to room temperature and the stirring is continiued for 1 hour. The suspended solid is recovered by filtration, washed with water and dried under vacuum at 60°C for 2 hours, to give 0.336 of the product, m.p. 203-205°C.
e) preparation of the title compound To a suspension of 5-bromo-5-(4'-biphenyl}barbituric acid (0.323 g) in 4.4 ml of ethanol 0.14 g of N-(2-hydroxyethyl)piperazine are added and the reaction mixture is refluxed for 2 hours. The suspended solid is filtered off and the resulting clear solution is treated 2 5 with 125 p.l of triethyiamine, then the solvent is evaporated off. The residue is redissolved in 2 ml of ethanol, from which crystallizes a solid which is stirred for 30 minutes, then it is filtered. The residue is recrystallized from ethanol to give 100 mg of the pure product, m.p. 225-226°C.
1H-NMR in d6-DMSO: 2.3-2.5 ppm (m, 6H); 2.65 ppm (m, 4H); 3.45 ppm (m, 2H);
4.4 ppm (s, 1H); 7.3-7.8 ppm (m, 9H); 11.6 ppm (s, 2H).
Example 26 5-(4'-biphenyl)-5-IN-(4-nitrophenyl)piperazinyljbarbituric acid A solution of 5-bromo-5-(4'-biphenyl)barbituric acid (0.359 g; example 25, step d) in 9 ml of methanol is added with 0.622 g of N-(4-nitrophenyl)piperazine and the mixture is refluxed for about 2 hours. The solvent is evaporated off and the residue is partitioned between water and ethyl acetate. The organic phase is separated, washed with brine and dried over sodium sulfate. The solvent is then evaporated under reduced pressure to give 0.74 g of a residue which is purified by silica gel chromatography (eluent:
methylene chloride/acetone 9:1) to give 400 mg of the product, m.p. 181°C.
'H-NMR in d6-DMSO: 2.8 ppm (m, 4H); 3.5 ppm (m, 4H); 7.00 ppm (d, 2H); 7.3-7.85 ppm (m, 9H); 8.05 ppm (d, 2H); 11.7 ppm (s, 2H).
Ezarnipte 27 5-(4'phenoxyphenyl)-5-[N-(2-h~xyethyl)piperazin~barbituric acid a) preparation of N-[(4'-phenoxybenzyl)thiocarbonyl]morpholine A mixture of (4'-phenoxyphenyl)methyiketone ( 19.1 g), morpholine (20 ml} and sulphur (4.32 g) is refluxed for 24 hours, then it is extracted with diethyl ether.
The organic phase is concentrated to dryness to give, after crystallization form a petroleum ether/ethyl acetate mixture 8:2 (600 ml), 12.2 g of the product, m.p. 75-77°C.
b) preparation of (4'-phenoxyphenyl)acetic acid A suspension of N-[(4'-phenoxybenzyl)thiocarbonyi]morpholine ( 1.725 g) in 87 ml of 2 0 10% potassium hydroxide is refluxed for 8 hours 30 minutes, then the reaction mixture is brought to room temperature and acidified with 1N hydrochloric acid. A white solid separates, which is stirred for 30 minutes and filtered. The solid is washed with water and dried under vacuum, to give 1.095 g of the product, m.p. 70-72°C.
c) preparation of ethyl (4'-phenoxyphenyl)acetate To a suspension of (4'-phenoxyphenyl)acetic acid (0.456 g) in 4 ml of ethanol is added para-toluensulfonic acid (0.076 g) and the resulting mixture is refluxed for 2 hours. The solvent is evaporated off, the residue is dissolved in diethyl ether and the organic phase is washed with saturated aqueous solution of sodium hydrogencarbonate and then with 3 0 brine. The organic phase is dried over sodium sulfate and concentrated to dryness to give 0.458 g of the product as a brown oil.
d) preparation of 5-(4'-phenoxyphenyl}barbituric acid A soultion of sodium ethoxide (0.27 g} in 3 mi of anhydrous ethanol is added with 0.657 3 5 g of ethyl (4'-phenoxyphenyl)acetate dissolved in 5 ml of ethanol, then with urea (0.18 g). The reaction mixture is refluxed for 2 hours 30 minutes, then it is cooled to room temperature and the suspended solid is filtered. The solid is redissolved in 8 ml of water and the solution is acidified with I N hydrochloric acid. The solid which separates is recovered by filtration to give 0.165 g ofthe product, m.p. >240°C.
e) preparation of 5-bromo-5-(4'-phenoxyphenyl)barbituric acid To a suspension of 5-(4'-phenoxyphenyl)barbituric acid (48 mg)in 0.23 ml of water, cooled at 0°C and under stirring, are added 23 p,l of 48% hydrobromic acid and successively 9 p.l of bromine. After 2 hours at room temperature additional 9 p.l of , bromine are added and stirring is continued for 2 hours. The suspended solid is then filtered and washed with water, to give, after drying under vacuum at 60°C, 57 mg of the product, m.p. 125-127°C.
f) preparation of the title compound A solution of 5-bromo-5-(4'-phenoxyphenyl)barbituric acid (50 mg) in 0.2 ml of methanol is added dropwise with a solution of N-(2-hydroxyethyl)piperazine (52 mg) in 0.6 ml of methanol and the mixture is stirred for 2 hours. The white precipitate is recovered by filtration and dried under vacuum at 60°C overnight. 42.6 mg of the product are obtained, m.p. >240°C.
1H-NMR in d6-DMSO: 2.2-2.45 ppm (m, 6H); 2.55 ppm (m, 4H); 3.45 ppm (m, 2H);
2 0 4.4 ppm (t, I H); 6.9-7.7 ppm (m, 9H); I 1.6 ppm (s, 2H).
Example 28 5-decyl-5-[N-(2-hydroxyethyllpiperazi~l]barbituric acid a) preparation of diethyl decylmalonate A solution of sodium (0.46 g) in 10 of anhydrous ethanol is added with 3.35 ml of diethyl malonate in 3 ml of ethanol and successively with a solution of decylbromide (4.15 mI) in 3 ml of ethanol.The reaction mixture is refluxed for 4 hours, then the precipitate is filtered off and the filtrate is concentrated to dryness. The residue is redissolved in a 3 0 saturated aqueous solution of sodium hydrogensulfate and it is extracted with ethyl acetate. The organic extract is dried over sodium sulfate and the solvent is evaporated off. The resulting residue is used as such in the successive reaction.
b) preparation of 5-decylbarbituric acid 3 5 To a solution of diethyl decylmalonate of step a) in 40 ml of ethanol are added 2.72 g of sodium ethoxide and then 1.8 g of urea. The reaction mixture is refluxed for 2 hours, then the precipitate is filtered and redissolved in 40 ml of water. The resulting aqueous solution is acidified with 6 N hydrochloric acid. The solid which separates is recovered by filtration and dried under vacuum at 40°C overnight. to give 2.152 g of the product, m.p. 190°C.
c) preparation of 5-bromo-5-decylbarbituric acid To a suspension of 5-decylbarbituric acid (0.537 g) in 2.9 ml of water are added under stirring a.t room temperature 0.29 ml of 48% hydrobromic acid. The mixture is cooled to 0°C and 0.113 ml of bromine are dropped. The reaction mixture is stirred at room temperature for 1 hour 30 minutes, then the white precipitate is filtered and it is washed 1o with water. The solid is partitioned between water and diethyl ether, the organic phase is separated, washed with brine and finally dried over sodium sulfate. By evaporation of the solvent under reduced pressure 0.62 g of the product are recovered.
d) preparation of the title compound To a solution of 5-bromo-5-decylbarbituric acid (0.619 g) in 1.3 ml of dimethylsulfoxide, kept under stirnng at 0°C, a solution of 0.93 g of N-(2-hydroxyethyl)piperazine in 0.7 ml of dimethylsulfoxide is added dropwise, then the reaction mixture is stirred at room temperature for 1 hour. The mixture is then cooled to 0°C and added with 30 ml of water. A white solid separates, which is kept under stirring for 1 hour, then is filtered and 2 0 dried under vacuum at 50°C. 0.309 g of the product are obtained, m.p. 181-182°C.
1H-NMR in d6-D1VIS0: 0.85 ppm (t, 3H); 0.9-1.1 ppm (m, 2H); 1.i5-1.4 ppm (m, 14H); 1.8-1.9 ppm (m, 2H); 2.2-2.45 ppm (m, 6H); 2.55 ppm (m, 4H); 3.45 ppm (m, 2H); 4.35 ppm (t, 1H); I 1.55 ppm (s, 2H).
Example 29 5-hexdecyl-5-[N-(2-h d~oxyethyl)t~iperazine]barbituric acid The title compound was prepared in an analogous manner like the compound of example 28.
Example 30 5-eicoxyl-5-[N-(2-hydroxyethyl)pinerazine]barbituric acid The title compound was prepared in an analogous manner like the compound of example 28.

Example 31 S-(4-butoxyphenyl)-5-[4-(2-hydroxyphenyl)piperazinylJbarbituric acid m.p. 184-I 85°
H-N.M.R. in d6-DMSO: 0.91 ppm (t, 3H); 1.4 ppm {m, 2H); 1.67 ppm (m, 2H}; 2,36 ppm (m, 6H); 2.55 ppm {m, 4H; 3.44 ppm (q, ZH); 3.95 ppm (t, 2H); 4.37 ppm (t, IH);
6.95 ppm {d, 2H); 7.28 ppm (d, 2H); I 1.5 ppm (br. s, 2H).
The compound is prepared as described in Example 14. The only difference is in the preparation of the starting material ethyl 4-butoxyphenyl acetate, which can be prepared starting from 4-hydroxyphenylacetic acid by esterification with ethanol (see example 14-a) and subsequent alkylation of ethyl 4-hydroxyphenyl acetate with butyl bromide alkylation of ethyl 4-hydroxyphenyl acetate with butyl bromide, according to know methodologies.
Example 32 The pathway of production as described in the specification and examplified in the previous examples the following compounds are synthesized. They are characterized by mass spectroscopy.
32.Name MW , exp.

mass O1 N-(2,4,6-Trioxo-5-phenyl-hexahydro-pyrimidin-5-yl}-323.3 323 benzamide 02 3-(3,4-Dimethoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-409.4 409 hexahydro-pyrimidin-5-yi)-acrylanvde 03 3-(3,4,5-Tnmethoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-439.4 439 hexahydro-pyrimidin-5-yl)-acrylamide 04 3-Phenyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-351.4 351 yl)-propionamide OS 5-Phenyl-pentanoic acid (2,4,6-trioxo-5-phenyl-hexahydro-379.4 379 pyrimidin-5-yl)-amide 06 2-{4-Nitro-phenyl}-N-(2,4,6-trioxo-5-phenyl-hexahydro-382.3 382 pyrimidin-5-yl)-acetamide 07 3-Benzenesulfonyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-415.4 415 pyrimidin-5-yl}-propionamide 08 2-(4-Bromomethyi-phenyl)-N-(2,4,6-trioxo-5-phenyl-430.3 429 hexahydro-pyrimidin-5-yl)-acetamide 09 2-Naphthalen-2-yl-N-(2,4,6-trioxo-5-phenyl-hexahydro-387.4 387 pyrimidin-5-yl)-acetamide 10 2-(3-Chloro-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-371.8 371 pyrimidin-5-yl}-acetamide 11 3-(2-Methoxy-phenyl}-N-(2,4,6-trioxo-5-phenyl-381.4 381 hexahydro-pyrimidin-5-yl)-propionamide 12 3-(4-Methoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-381.4 381 hexahydro-pyrimidin-5-yl)-propionamide 13 2-(3-Bromo-phenyl)-N-(2,4,6-trioxo-S-phenyl-hexahydro-416.2 415 pyrimidin-5-yl)-acetamide 14 3-Phenyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-349.3 yl)-acrylamide I S 4-Bromo-N-{2 4,6-trioxo-5-phenyl-hexahydro-pyrimidin-402.2 401 ' S-yl)-benzamide 16 3-Methyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-337.3 337 5-yl)-benzamide ' 17 4-Methylsulfanyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-369.4 369 pyrimidin-5-yl)-benzamide 18 3-Chloro-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-357.8 yl)-benzamide 19 4-Chloro-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-357.8 yl)-benzamide 20 3,4-Dimethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-351.4 351 pyrimidin-5-yl)-benzamide 21 3,5-Dimethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-351.4 351 pyrimidin-5-yl)-benzamide 22 4-Ethoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-367.4 367 5-yl)-benzamide 23 4-Cyano-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-348.3 348 yl)-benzamide 24 3-Methoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-353.3 353 5-yl)-benzamide 25 4-Methoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-353.3 353 5-yl)-benzamide 26 2-Methyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-337.3 337 5-yl)-benzamide 27 2,4-Difluoro-N-(2,4,6-trioxo-5-phenyl-hexahydro-359.3 359 pyrimidin-5-yl)-benzamide 28 N-(2,4,6-Trioaco-5-phenyl-hexahydro-pyrimidin-5-yl)-324.3 324 isonicotinamide 29 Naphthalene-1-carboxylic acid (2,4,6-trioxo-5-phenyl-373.4 373 hexahydro-pyrimidin-5-yl)-amide 30 1-(4-Fluoro-phenyl)-3-(2,4,6-trioxo-5-phenyl-hexahydro-356.3 356 pyrimidin-5-yi)-urea 31 3-(4-Methoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-379.4 379 hexahydro-pyrimidin-5-yl}-acrylamide 32 1-(3-Trifluoromethyl-phenyl)-3-(2,4,6-trioxo-5-phenyl-406.3 406 hexahydro-pyrimidin-5-yl}-urea 33 3-(4-Chioro-phenyl)-N-{2,4,6-trioxo-5-phenyl-hexahydro-383.8 383 pyrimidin-5-yl)-acrylamide 34 1-(2,4-Dichloro-phenyl}-3-(2,4,6-trioxo-5-phenyl-407.2 406 hexahydro-pyrimidin-5-yl)-urea 35 1-(3,4-Dichloro-phenyl)-3-(2,4,6-trioxo-5-phenyl-407.2 406 hexahydro-pyrimidin-5-yl)-urea 3b I-{Chlor-phenyl)-3-(2,4,6-trioxo-5-phenyl-hexahydro-372.7 372 pyrimidin-5-yl)-urea 37 I-{4-Methoxy-phenyl)-3-{2,4,6-trioxo-5-phenyl-368.4 368 hexahydro-pyrimidin-5-yl)-urea 38 1-Phenyl-3-{2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-338.3 yl)-urea 39 Naphthalene-2-carboxylic acid (2,4,6-trioxo-5-phenyl-373.4 373 hexahydro-pyrimidin-5-yl}-amide 40 IH-Indole-5-carboxylic acid (2,4,6-trioxo-5-phenyl-362.3 362 hexahydro-pyrimidin-5-yl)-amide 41 N-(2,4,6-Tnoxo-5-phenyl-hexahydro-pyrimidin-5-yl)-366.3 366 terephthalamide 42 4-Sulfamoyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-402.4 402 pyrimidin-5-yl)-benzamide 43 4-Methyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-337.3 337 5-yl)-benzamide 44 4-Ethyl-N-{2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-351.4 351 yl)-benzamide 45 4-Methyl-N-{2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-373.4 373 5-yl)-benzenesulfonamide 46 4-Bromo-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-438.3 437 5-yl)-benzenesulfonamide 47 2-Trifluoromethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-427.4 427 pyrimidin-5-yl)-benzenesulfonamide 48 5-Phenyl-5-(4-phenyl-piperidin-I-y1)-pyrimidine-2,4,6-363.4 363 trione 49 2,3-Dimethoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-383.4 383 pyrimidin-5-yl)-benzamide 50 2,3-Dimethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-351.4 351 pyrimidin-5-yl)-benzamide 51 4-Hydroxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-339.3 411 5-yl)-benzamide silyl.

52 3,4-Dimethoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-383.4 383 pyrimidin-5-yl)-benzamide 53 3-Dimethylanuno-N-(2,4,6-trioxo-5-phenyl-hexahydro-366.4 366 pyrimidin-5-yl)-benzamide 54 3-tent-Butyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-379.4 379 pyrimidin-5-yl)-benzamide 55 3,4-Dimethoxy-2-nitro-N-(2,4,6-trioxo-5-phenyl-428.4 428 +

hexahydro-pyrimidin-5-yl)-benzamide FAB

56 4-Butoxy-3-methoxy-N-{2,4,6-trioxo-5-phenyl-hexahydro-425.4 425 +

pyrimidin-5-yl)-benzamide FAB

57 2-Methyl-2,3-dihydro-benzofuran-7-carboxylic 379.4 379 acid +
(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide FAB

58 1H-Indole-4-carboxylic 362.3 362 acid {2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide 59 4-Methyl-3-sulfamoyl-N-{2,4,6-trioxo-5-phenyl-416.4 416 hexahydro-pyrimidin-5-yl)-benzamide 60 Acetic 440.4 440 acid +
6-methyl-2-nitro-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yIcarbamoyl)-phenyl FAB
ester 61 Carbonic 441.4 441 acid +
ethyl ester 2-methoxy-4-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-ylcarbamoyl)-phenyl FAB
ester 62 2-Bromo-3-nitro-N-(2,4,6-trioxo-5-phenyl-hexahydro-447.2 446 pyrimidin-5-yI)-benzamide 63 "4-Chloro-3-sulfamoyl-N-(2,4,6-trioxo-5-phenyl-436.8 436 hexahydro-pyrimidin-5-yl)-benzamide e"

65 3-tert-Butyl-2-hydroxy-N-(2,4,6-trioxo-5-phenyl-395.4 395 hexahydro-pyrimidin-5-yl)-benzamide 66 4'-Benzyloxy-biphenyl-3-carboxylic 505.5 505 acid +
(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidein-5-yl)-amide FAB

67 3-Cyano-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-348.3 348 yl)-benzamide 68 3-Bromo-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-402.2 401 5-yl)-benzamide 69 3-Phenoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-415.4 415 +

S-yl)-benzamide FA.B

70 3-Benzoyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-427.4 427 5-yl)-benzamide 71 3-Trifluoromethyi-N-(2,4,6-trioxo-5-phenyl-hexahydro-391.3 391 pyrimidin-5-yl)-benzamide 72 N-(2,4,6-Trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-381.3 381 isophthalamic acid methyl ester 73 9H-Fluorene-1-carboxylic acid (2,4,6-trioxo-5-phenyl-4I 1.4 411 hexahydro-pyrimidin-5-yl)-amide 74 9-Oxo-9H-fluorene-1-carboxylic acid (2,4,6-trioxo-5-425.4 425 phenyl-hexahydro-pyrimidin-5-yl)-amide 75 5-Phenyl-5-(4-phenyl-piperazin-1-yl)-pyrimidine-2,4,6-364.4 364 triune 76 5-Phenyl-5-[4-(2-trifluoromethyl-phenyl)-piperazin-1-yl]-432.4 pyrimidine-2,4,6-triune 77 5-j4-{4-Nitro-phenyl)-piperazin-1-yl]-5-phenyl-pyrimidine-409.4 2,4,6-triune 78 5-(4-Phenethyl-piperazin-1-yl)-5-phenyl-pyrimidine-2,4,6-392.5 triune 79 5-[4-(3-Methoxy-phenyl)-piperazin-1-yl]-5-phenyl-394.4 394 pyrimidine-2,4,6-triune 80 3-Acetylamino-N-(2,4,6-trioxo-5-phenyl-hexahydro-380.4 380 pyrimidin-5-yl)-benzamide 81 Acetic acid 3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-381.3 S-ylcarbamoyl)-phenyl ester 82 3-Ethoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-367.4 367 5-yl)-benzamide 83 5-Phenyl-5-(4-pyridin-4-yl-piperazin-1-yl)-pyrimidine-365.4 365 2,4,6-triune 84 5-Phenyl-5-j4-{3-trifluoromethyl-phenyl)-piperazin-1-yl]-432.4 pyrimidine-2,4,6-triune 85 5-j4-(4-Methoxy-phenyl)-piperazin-1-yI]-S-phenyl-394.4 394 pyrimidine-2,4,6-triune 86 5-(4-Benzhydryl-piperazin- i -yl)-5-phenyl-pyrimidine-454.5 454 +

2,4,6-triune F~

87 5-Phenyl-5-[4-(3-phenyl-allyl)-piperazin-1-yl]-pyrimidine-404.5 +

2,4,6-triune F~

88 5-Phenyl-5-(2-pyrrolidin-1-yl-ethylamino)-pyrimidine-3 i 6.4 316 2,4,6-triune 89 5-[2-(3H-Imidazol-4-yl)-ethylamino]-5-phenyl-pyrimidine-313.3 313 +

2,4,6-triune F~

Ezample 33 In order to determine the inhibition of MMPs, for example HNC, the catalytic domain (isolation and purification see for example Schnierer, S., Kleine, T., Gote, T., HiIIemann, A., Knauper, V., Tschesche, H.,Biochem. Biophys. Res. Common. (1993) 19I, 319-326}
is incubated with inhibitors having various concentrations. Subsequently, the initial reaction rate in the conversion of a standard substrate is measured in a manner analogous to Grams F. et al., FEBS 335 (I993) 76-80).

WO 97/23465 PCTlEP96/05766 The results are evaluated by plotting the reciprocal reaction rate against the concentration of the inhibitor. The inhibition constant (Ki) is obtained as the negative section of the abscissis by the graphical method according to Dixon, M., Biochem. J.
(1953) 55, 170-202.
The synthetic collagenase substrate is a heptapeptide which is coupled, at the C-terminus, with DNP (dinitrophenol). Said DNP residue quenches by steric hindrance the fluorescence of the adjacent tryptophane of the heptapeptide. After cleavage of a tripeptide which includes the DNP group, the tryptophane fluorescence increases. The proteolytic cleavage of the substrate therefore can be measured by the fluorescence value.
a) First method The assay was performed at 25 °C in a freshly prepared 50 mM Tris buffer (pH 8.0) treated with dithiozone to remove traces of heavy metals. 4 mM CaClz was added and the buffer saturated wtih argon. Stock solutions of adamalysin II were prepared by centrifugation of the protein from ~.n ammonium sulfate suspension and subsequent dissolution in the assay buffer. Stock solutions of collagenase were diluted with the assay buffer. Enzyme concentrations were determined by uv measurements (sago = 2.8 crri', s288: 2.2 104 M' . cm') and the stock solutions were stored in the cold.-This solution was diluted 1:100 to obtain the final 16 nM assay concentration. The fluorogenic substrate DNP-ProLeu-Gly-LeuTrp-Ala-D-Arg-NHZ with a Km of 52 pM
was used at a concentration of 21.4 pM; for the K; determination a 12.8 pM
concentration has also been used. Substrate fluorescence was measured at an excitation and emission wavelength of ~, = 320 and 420 nm, respectively, on a spectrofluorimeter (Perkin Elmer, Model 650-40) equipped with a thermostated cell holder.
Substrate hydrolysis was monitored for 10 min. immediately after adding the enzyme. All reactions were performed at least in triplicate. The K; values-of the inhibitors were calculated from the intersection point of the straight lines obtained by the plots of v~/v;
vs. [concentration 3 0 of inhibitor], whereas ICto values were calculated from plots of v;/v° [concentration of inhibitor] by non-linear regression with simple robust weighting.
b) Second method 3 5 Assay buffer:
50 mM Tris/HCI pH 7.6 (Tris= Tris-(hydroxymethyl)-aminomethan) 100 mM NaCI/ 10 mM CaC 12/5 % MeQH {ff necessary) Enzyme: 8 nM catalytic domain (Met80-G1y242) of human neutrophil collagenase Substrate: 10 microM DNP-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2 Total assay volume: I ml A solution of the enzyme and inhibitor in assay buffer (25 °C) was prepared. The reaction was started directly by giving the substrate into the solution. The cleavage of the flourogenic substrate was followed by flourescence spectroscopy with an excitation and envision wavelength of 280 and 350 nm, respectively. The ICso value was caicuIated as the inhibitor concentration, which is necessary to decrease the velocity of the reaction to the half in comparison to the reaction without inhibitor.
Table 1 shows the ICso values found.
Table 1: IC50 Values of MMP-Inhibitor (MMP-8 Compound IC-50 nM

examle 32.74 890 referred 150 no.

examle 25 140 examIe 23 110 examIe 20 860 examle 32.77 160 referred 60 no.

examle 28 320 examle 26 15

Claims (20)

Claims:
1 . A compound of formula I:
in which X, Y and Z are all oxygen, R1 represents a group W-V, in which W is a valency bond or a straight-chained or branched C1-C8 alkyl or a C2-C8 alkenyl group which is unsubstituted or substituted one to five times, V is an unsubstituted or substituted monocycle or bicycle which can contain one, two or three heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, or W-V is a C1-C20 alkyl group which can be interrupted by nitrogen, oxygen or sulphur, and wherein one to five carbon atoms are unsubstituted or substituted, R2 and R3 are both hydrogen, R4 and R5 each independently represent A-D, wherein A represents a valency bond, C1-C8 alkyl, C2-C8 alkenyl, C1-C8 acyl, C1-C8 alkylsulfonyl, sulfonyl, C1-C8 alkylaminocarbonyl, aminocarbonyl, C1-C8 alkoxycarbonyl, oxy-carbonyl, C1-C8 alkylaminothiocarbonyl or aminothio-carbonyl which is unsubstituted or substituted one to five times, D represents hydrogen, a monocycle or bicycle, the monocycle or bicycle being uninterrupted or interrupted one, two or three times by nitrogen, oxygen or sulphur, and the monocycle or bicycle is unsubstituted one to five times, or R4 and R5 together with the nitrogen atom to which they are bound, represent a ring which is uninterrupted or interrupted by a further N atom, said ring being uncondensed or condensed to a monocycle or bicycle; said ring being unsubstituted or substituted one to five times, independently, by a residue selected from hydroxy, C1-C8 -alkoxy, amino, C1-C8 -alkylamino, di- C1-C8-alkylamino, nitrile and E-G wherein E represents a valency bond, C1-C8 -alkyl, C2-C8 -alkenyl, C1-C8 -aryl, C1-C8 -alkylsulfonyl, sulfonyl, C1-C8 -alkylaminocarbonyl, aminocarbonyl, C1-C8 -alkoxycarbonyl, oxycarbonyl, C1-C8 -alkylaminothiocarbonyl and aminothiocarbonyl which is unsubstituted or substituted; and G represents hydrogen, a monocycle or bicycle, the monocycle or bicycle being uninterrupted or interrupted one, two or three or times by nitrogen, oxygen or sulphur and the monocycle or bicycle being unsubstituted or substituted one to five times, said monocycle listed in R1, R4 and R5 being a saturated or unsaturated ring system with 3 - 8, carbon atoms which is uninterrupted or interrupted one, two or three times by nitrogen, oxygen or sulphur, said bicycle listed in R1, R4 and R5 being a condensed bicycle or a bicyC1e of the type monocyclel-L-monocycle2, wherein L denotes a valency bond, C1-C4-alkyl group, C2-C4-alkenyl group, an oxygen or a -C(O)-group, the non-cyclic residues listed under R1, R4 and R5 when substituted are substituted one to five times by a substituent selected from halogen, hydroxy, thio, C1-C8-alkyl, hydroxy-C1-C8-alkyl, C1-C8-alkoxy, C1-C8-alkylthio, C1-C8-alkylsulfinyl;
C1-C8-alkyl-sulfonyl, amino, C1-C8-alkylamino, di- C1-C8-alkylamino, nitro, carboxyl, carboxamido, C1-C8-alkoxycarbonyl, and aminocarbonyl which aminocarbonyl is unsubstituted or substituted once or twice by C1-C6-alkyl, nitrite, oxo, thiocarboxamido, C1-C8-alkoxythiocarbonyl, C1-C8-alkyl-mercaptocarbonyl, phosphono, C1-C8-alkylphosphono, di- C1-C8-alkylphosphono, C1-C8-alkylsulfonylamido, arylamino, aryl, hetaryl, aryloxy, arylthio, arylsulfinyl, arylsulfonyl or C1-C8-acyl, wherein aryl represents a phenyl or naphthyl residue and hetaryl is selected from the group consisting of pyridinyl, pyrazinyl, piperazinyl, imidazolyl, thiazolyl, thiophenyl and indolyl;
the monocycles and bicycles listed under R1, R4 and R5 when substituted are substituted by substituents selected from halogen, nitro, hydroxyl, C1-C8 alkoxy, amino, C1-C8 alkylamino, di C1-C8 alkylamino, halomethyl, dihalomethyl, trihalomethyl, phosphono, C1-C8 alkylphosphono, di C1-C8 alkylphosphono, SO2NH2, SO2NH (C1-C8 alkyl), SO2N(C1-C8 alkenyl)2, SO2(C1-C8 alkyl), acetyl, formyl, nitrite, COOH, COO(C1-C8) alkyl, OC(O)C1-C8alkyl, -NHC(O)O(C1-C8) alkyl, OC(O)O-phenyl, OC(O)O-naphthyl, -NHC(S)NH2, -NHC(S)NH(C1-C8) alkyl, NHC(O)-phenyl and HNC(O)-naphthyl;

or a pharmacologically acceptable salt or optically active form thereof, provided that when -NR4R5 represents an unsubstituted piperidine ring, then R1 is other than phenyl, methyl, ethyl, propyl, allyl or crotonyl and when -NR4R5 represents a N,N-diethylamino group, then R1 is other than methyl, ethyl or crotonyl.
2. A compound of formula 1 as claimed in claim 1, in which monocycle denotes for a cyclopentyl, cyclohexyl, cycloheptyl, morpholinyl, thiamorpholinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyi, furyl, thiophenyl, imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl or 1,2,4-triazolyl residue.
3. A compound of formula I as claimed in claim 1, in which hetaryl is pyridinyl, imidazolyl or thiophenyl.
4. A compound of formula I as claimed in claim 1 or 2, in which bicycle denotes a naphthyl, tetrahydronaphthyl, dekalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, indazolyl, oxindolyl, benzofuranyl, benzothiophenyl, benzthiazolyl, benzoxazolyl, purinyl, biphenyl or (4-phenoxy)phenyl residue.
5. A compound of formula I as claimed in claim 1 or 2, in which bicycle denotes a naphthyl, biphenyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, indolyl or benzimidazolyl residue.
6. A compound of formula I as claimed in any one of claims 1 to 5, in which W of R1 is methyl, ethyl, butyl or hexyl residue; and V is a phenyl, pyridyl or imidazolyl residue.
7. A compound of formula I as claimed in any one of claims 1 to 5, in which W-V denote for n-octyl, n-decyl, biphenyl or octyl or decyl type residues having two or three oxygen atoms or biphenyl-type residues having one or two nitrogen atoms.
8. A compound of formula I as claimed in any one of claims 1 to 7, in which the R4 and R5 and the nitrogen to which they are attached form a piperazinyl or piperidinyl, both of which are substituted at the 4-position.
9. A process for the production of a compound of formula I as defined in claim 1, or a pharmacologically acceptable salt thereof, wherein:

a) a compound of the general formula II:

in which X, Y, Z, R1, R2 and R3 are as defined in claim 1, and T represents a leaving group is reacted with a compound of the general formula III:

in which R4 and R5 are as defined in claim 1; or b) a compound of the general formula IV:

in which R1, R4, R5, Y and Z are as defined in claim 1, and R7 is methyl, ethyl or phenyl, is reacted with a compound of the general formula V:

in which R2, R3 and X are as defined in claim 1; or c) in the case where at least one of R4 and R5 represents an acyl, alkylsulfonyl, arylsulfonyl, alkylamino-carbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminothiocarbonyl or arylaminothiocarbonyl residue, a compound of the general formula VI:

in which X, Y, Z, R1, R2 and R3 are as defined in claim 1, is reacted with a compound of the general formula VII or VIII:

R8-D-Hal (VII) R8N=C=A (VIII) in which R8 represents an unsubstituted or substituted alkyl or aryl residue, D is C(O) , O-C(O), SO2 or a valency bond, Hal is chlorine, bromine or iodine and A represents oxygen or sulphur; and when a salt of the compound (I) is required, converting the compound (I) obtained into a pharmacologically acceptable salt thereof, and when an optically active form of the compound (I) is required, converting the compound (I) into an optically active form thereof.
10. A process according to claim 9 a) wherein said leaving group is Hal or OSO2R6, wherein Hal is chlorine, bromine or iodine, and R6 is methyl, phenyl or naphthyl.
11. A pharmaceutical composition containing at least one compound of formula I as claimed in any one of claims 1 to 8, or a pharmacologically acceptable salt thereof, or an optically active form thereof, or a prodrug thereof, in association with a pharmaceutically acceptable carrier.
12. Use of a compound of formula I:

in which:
X, Y and Z are independently of one another oxygen, sulphur or NH, R1 represents a group W-V, W is a valency bond or a straight-chained or branched C1-C8 alkyl or a C2-C8 alkenyl group which is unsubstituted or substituted one to five times, V is an unsubstituted or substituted monocycle or bicycle which can contain one, two or three heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, or W-V is a C1-C20 alkyl group which can be interrupted by nitrogen, oxygen or sulphur, and wherein one to five carbon atoms are unsubstituted or substituted, R2 and R3 represent hydrogen or one of the two represents lower alkyl or lower acyl;

R4 and R5 together with the nitrogen atom to which they are bound, represent a ring which is uninterrupted or interrupted by a further N atom, said ring being uncondensed or condensed to a monocycle or bicycle; said ring being unsubstituted or substituted one to five times, independently, by a residue selected from hydroxy, C1-C8 -alkoxy, amino, C1-C8 -alkylamino, di- C1-C8 -alkylamino, nitrite and E-G wherein E represents a valency bond, C1-C8 -alkyl, C2-C8 -alkenyl, C1-C8 -acyl, C1-C8 -alkylsulfonyl, sulfonyl, C1-C8-alkylaminocarbonyl, aminocarbonyl, C1-C8 -alkoxycarbonyl, oxycarbonyl, C1-C8 alkylaminothiocarbonyl and aminothiocarbonyl which is unsubstituted or substituted; and G represents hydrogen, a monocycle or bicycle, the monocycle or bicycle being uninterrupted or interrupted one, two or three or times by nitrogen, oxygen or sulphur and the monocycle or bicycle being unsubstituted or substituted one to five times, said monocycle listed in R1, R4 and R5 being a saturated or unsaturated ring system with 3-8, carbon atoms which is uninterrupted or interrupted one, two or three times by nitrogen, oxygen or sulphur, said bicycle listed in R1, R4 and R5 being a condensed bicycle or a bicycle of the type monocycle1-L-monocycle2, wherein L denotes a valency bond, C1-C4-alkyl group, C2-C4 alkenyl group, an oxygen or a -C(O)-group, the non-cyclic residues listed under R1, R4 and R5 when substituted are substituted one to five times by a substituent selected from halogen, hydroxy, thio, C1-C8-alkyl, hydroxy C1-C8-alkyl, C1-C8-alkoxy, C1-C8-alkylthio, C1-C8-alkylsulfinyl, C1-C8-alkyl-sulfonyl, amino, C1-C8-alkylamino, di- C1-C8-alkylamino, nitro, carboxyl, carboxamido, C1-C8-alkoxycarbonyl, and aminocarbonyl which aminocarbonyl is unsubstituted or substituted once or twice by C1-C6-alkyl, nitrite, oxo, thiocarboxamido, C1-C8-alkoxythiocarbonyl, C1-C8-alkyl-mercaptocarbonyl, phosphono, C1-C8-alkylphosphono, di- C1-C8-alkylphosphono, C1-C8-alkylsulfonylamido, arylamino, aryl, hetaryl, aryloxy, arylthio, arylsulfinyl, arylsulfonyl or C1-C8-aryl, wherein aryl represents a phenyl or naphthyl residue and hetaryl is selected from the group consisting of pyridinyl, pyrazinyl, piperazinyl, imidazolyl, thiazolyl, thiophenyl and indolyl;

the monocycles and bicycles listed under R1, R4 and R5 when substituted are substituted by substituents selected from halogen, nitro, hydroxyl, C1-C8 alkoxy, amino, C1-C8 alkylamino, di C1-C8 alkylamino, halomethyl, dihalomethyl, trihalomethyl, phosphono, C1-C8 alkylphosphono, di C1-C8 alkylphosphono, SO2NH2, SO2NH (C1-C8 alkyl), SO2N(C1-C8 alkenyl)2, SO2(C1-C8 alkyl), acetyl, formyl, nitrite, COOH, COO(C1-C8) alkyl, OC(O)C1-C8 alkyl, -NHC(O)O (C1-C8) alkyl, OC(O)O-phenyl, OC(O)O-naphthyl, -NHC(S)NH2, -NHC(S)NH(C1-C8) alkyl, NHC(O)-phenyl and HNC(O)-naphthyl;
Or or a pharmacologically acceptable salt, optically active form or prodrug thereof, for the production of a pharmaceutical agent having matrix metalloprotease inhibitory action.
13. Use of a compound of formula I as defined in claim 12, or a pharmacologically acceptable salt, optically active form or prodrug thereof, for the production of a pharmaceutical agent having inhibitory action on adamalysins.
14. Use of a compound of formula I as defined in any one of claims 1 to 8, or a pharmacologically acceptable salt, optically active form or prodrug thereof, in the manufacture of a medicament having matrix metalloprotease inhibitory action.
15. Use of a compound of formula I as defined in any one of claims 1 to 8, or a pharmacologically acceptable salt, optically active form or prodrug thereof, in the manufacture of a medicament having inhibitory action on an adamalysin.
16. A compound of formula I:

wherein X, Y and Z are each oxygen;
R1 is selected from the group consisting of (a) n-octyl, (b) n-decyl, (c) biphenyl and (d) (4-phenoxy)phenyl, wherein the terminal monocycle for moieties (c)-(d) is unsubstituted or substituted by a substituent selected from the group consisting of -NH2, -NO2, -SO2NH2, -SO2CH3, acetyl, hydroxy, methoxy, ethoxy, cyano and halogen;
R2 and R3 are each hydrogen; and R4 and R5, together with the nitrogen atom to which they are bound, form a piperazinyl or piperidyl ring, unsubstituted or substituted with a substituent selected from the group consisting of:
i) phenyl, pyridyl or pyrazidyl, unsubstituted or substituted by amino, nitro, -SO2NH2, -SO2 lower alkyl, SO2NH lower alkyl, hydroxyl, lower alkoxy, nitrile, lower alkylamino, lower dialkylamino, ii) hydroxyl C1-C6 alkyl; or a pharmacologically acceptable salt thereof.
17. The compound of claim 16, or a pharmacologically acceptable salt thereof, wherein piperazinyl is substituted with a substituent selected from the group consisting of phenyl, pyridyl and pyrazinyl.
18. The compound of claim 16, wherein the compound is selected from the group consisting of 5-octyl-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid;
5-(4'-biphenyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid;
5-(4'-biphenyl)-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid;
5-decyl-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid; and 5-[4-(4-nitrophenyl)piperazinyl]-5-octyl-barbituric acid.
19. The compound of claim 16, wherein the compound is 5-(4'-biphenyl)-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid.
20. A pharmaceutical composition suitable for use as a matrix metalloprotease inhibitor, comprising a compound of formula (I) as defined in claim 16, 17, 18 or 19, or a pharmacologically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
CA002240845A 1995-12-23 1996-12-20 New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds Expired - Fee Related CA2240845C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19548624.2 1995-12-23
DE19548624A DE19548624A1 (en) 1995-12-23 1995-12-23 New barbituric acid derivatives, processes for their preparation and medicaments containing these compounds
PCT/EP1996/005766 WO1997023465A1 (en) 1995-12-23 1996-12-20 New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds

Publications (2)

Publication Number Publication Date
CA2240845A1 CA2240845A1 (en) 1997-07-03
CA2240845C true CA2240845C (en) 2006-09-19

Family

ID=37057008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002240845A Expired - Fee Related CA2240845C (en) 1995-12-23 1996-12-20 New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds

Country Status (1)

Country Link
CA (1) CA2240845C (en)

Also Published As

Publication number Publication date
CA2240845A1 (en) 1997-07-03

Similar Documents

Publication Publication Date Title
EP0869947B1 (en) Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
EP0989982B1 (en) Barbituric acid derivatives with antimetastatic and antitumor activity
JP2003523335A (en) Pyrimidin-4-one derivatives as LDL-PLA2 inhibitors
JP2002523493A (en) Arylpiperazines and their use as metalloproteinase inhibitors (MMPs)
AU768309B2 (en) New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
CA2240845C (en) New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
AU722513C (en) New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
AU2002302470B2 (en) Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
AU2002302470A1 (en) Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed